STOCK TITAN

Adia Med posts $53K Q3 loss, flags going-concern doubt

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

Adia Med, Inc. (ADIA) reported third-quarter 2026 revenue of $454,385, versus $332,048 a year earlier, and nine-month revenue of $1,019,245 versus $521,958. It recorded a quarterly net loss of $53,015, compared with $70,376 net income, and a nine-month net loss of $271,922 versus $169,839. Nine-month operating cash use was $239,653.

ADIA disclosed substantial doubt about its ability to continue as a going concern, citing losses and dependence on higher revenue and outside capital. On September 30, 2026, ADIA and subsidiary Adia Labs agreed to sell 30% of Adia Labs to Live Oak Health LLC, doing business as QCM Biologics, for $1.5 million: $1 million cash and a $500,000 note. The buyer may purchase up to 10 more units at $50,000 each through September 30, 2028; if fully exercised and no other units are issued or transferred, ADIA would own 60%, with each side holding 50% of voting power.

The revised June 2026 statements reduce revenue and net income by $96,800 for the three- and six-month periods. Working capital was $128,369 at September 30, 2026.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 2 points

How the balance works

Positive

  • Moderate pointNine-month revenue reached $1,019,245, versus $521,958 a year earlier.

Negative

  • Major pointGoing-concern substantial doubt; accumulated deficit was $16,245,404.
  • Moderate pointNine-month net loss increased to $271,922 from $169,839.

Filing Explained

The subsidiary sale is recorded as completed, while a separate future preferred-share issuance obligation could dilute existing common holders.

The report records the September 30, 2026 sale of Adia Labs membership units as completed: Adia Med received $1,000,000 in cash and holds a $500,000 note receivable; the sale transferred subsidiary units, not ADIA common shares.

Separately, the company says it must issue 15,000,000 Series C preferred shares to two officers in the future, regardless of option exercise; each Series C share is convertible into four common shares, so issuance and conversion would increase the common share count and reduce existing holders’ percentage ownership.

The note bears 7% interest, requires monthly interest-only payments for 48 months beginning October 30, 2026, and is due in full on September 30, 2030; the purchased units secure the note.

Third-quarter revenue $454,385 Three months ended September 30, 2026; $332,048 in 2025.
Third-quarter net loss ($53,015) Three months ended September 30, 2026; net income of $70,376 in 2025.
Nine-month revenue $1,019,245 Nine months ended September 30, 2026; $521,958 in 2025.
Nine-month net loss ($271,922) Nine months ended September 30, 2026; ($169,839) in 2025.
Cash used in operating activities ($239,653) Nine months ended September 30, 2026; ($108,521) in 2025.
Cash $1,137,818 Balance at September 30, 2026.
Adia Labs stake-sale consideration $1,500,000 Consideration for 30% of Adia Labs; $1,000,000 cash and a $500,000 promissory note.
Working capital $128,369 At September 30, 2026.
going concern financial
"prepared on a going concern basis"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
working capital financial
"working capital of $128,369"
Working capital is the money a business has available to cover its daily expenses, like paying bills and buying supplies. It’s like the cash in your wallet that helps you handle everyday costs; having enough ensures the business can operate smoothly without running into money shortages.
promissory note financial
"delivery of a promissory note"
A promissory note is a written IOU in which one party promises to pay a specific sum, often with interest, to another party by a set date or on demand. Investors care because it functions like a loan: it creates a legal claim on future cash flows, carries credit and timing risk, and can affect valuation or liquidity—think of it as a formal, tradable promise to be repaid that can be assessed like any other debt investment.
first-priority pledge technical
"secured by a first-priority pledge of the membership interest"
A first-priority pledge is a security arrangement in which a creditor is given the top-ranking lien on specific pledged assets, meaning that if the borrower defaults or is liquidated the creditor has the legal right to seize and be paid from those assets before any other secured creditors. Priority is established and preserved by taking and maintaining a perfected security interest (for example, by possession of collateral or by filing the appropriate public financing statement), and it can be displaced only by earlier perfected liens, certain statutory liens or specific carve-outs set out in law or contract. The practical effect is that the pledged assets serve as the primary source of repayment for that creditor while the borrower is restricted from granting later liens that would outrank the first-priority claim.
ASC 606 technical
"collectively, ASC 606"
A U.S. accounting standard that sets consistent rules for when and how companies record revenue from contracts with customers, focusing on the transfer of promised goods or services. It matters to investors because it affects the timing and amount of reported sales and profit—like deciding whether a contractor can count payment when a job starts, progresses, or finishes—so it improves comparability and helps assess a company's true economic performance.
right-of-use asset technical
"Right of use asset - operating lease, net"
A right-of-use asset is the value a company records on its balance sheet for the practical use of something it leases — like the benefit of living in a rented office or using leased equipment for a set period. Investors care because it turns many leases into on-balance-sheet assets and matching liabilities, which can change reported leverage, asset base and performance metrics much like taking on a loan would.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Adia Med (ADIA)'s third-quarter 2026 revenue and earnings?

ADIA reported revenue of $454,385 and a net loss of $53,015 for the three months ended September 30, 2026. The year-earlier quarter had revenue of $332,048 and net income of $70,376.

What option did Adia Med (ADIA) give the Adia Labs buyer?

The buyer may purchase up to 10 additional Adia Labs units at $50,000 per unit through 5 p.m. Eastern Time on September 30, 2028. The option may be exercised in whole units, in one or more exercises, and may not be assigned without ADIA's prior written consent except to an affiliate wholly owned by David Konn.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false --12-31 2026 Q3 0001160420 0 0 0 0 0 0 0 0 0 0.001 0.001 0 0 0 0 3 3 2 2 0001160420 2026-01-01 2026-09-30 0001160420 2026-11-16 0001160420 2026-09-30 0001160420 2025-12-31 0001160420 ADIA:BiologicsMember 2026-09-30 0001160420 ADIA:BiologicsMember 2025-12-31 0001160420 ADIA:PrepaidInventoryMember 2026-09-30 0001160420 ADIA:PrepaidInventoryMember 2025-12-31 0001160420 ADIA:Special2022SeriesAPreferredStockMember 2026-09-30 0001160420 ADIA:Special2022SeriesAPreferredStockMember 2025-12-31 0001160420 us-gaap:SeriesAPreferredStockMember 2026-09-30 0001160420 us-gaap:SeriesAPreferredStockMember 2025-12-31 0001160420 us-gaap:SeriesCPreferredStockMember 2026-09-30 0001160420 us-gaap:SeriesCPreferredStockMember 2025-12-31 0001160420 us-gaap:CommonClassAMember 2026-09-30 0001160420 us-gaap:CommonClassAMember 2025-12-31 0001160420 us-gaap:CommonClassBMember 2026-09-30 0001160420 us-gaap:CommonClassBMember 2025-12-31 0001160420 2026-07-01 2026-09-30 0001160420 2025-07-01 2025-09-30 0001160420 2025-01-01 2025-09-30 0001160420 ADIA:SalesOfSupplementsMember 2026-07-01 2026-09-30 0001160420 ADIA:SalesOfSupplementsMember 2025-07-01 2025-09-30 0001160420 ADIA:SalesOfSupplementsMember 2026-01-01 2026-09-30 0001160420 ADIA:SalesOfSupplementsMember 2025-01-01 2025-09-30 0001160420 ADIA:MedicalProceduresMember 2026-07-01 2026-09-30 0001160420 ADIA:MedicalProceduresMember 2025-07-01 2025-09-30 0001160420 ADIA:MedicalProceduresMember 2026-01-01 2026-09-30 0001160420 ADIA:MedicalProceduresMember 2025-01-01 2025-09-30 0001160420 ADIA:SalesOfBiologicsMember 2026-07-01 2026-09-30 0001160420 ADIA:SalesOfBiologicsMember 2025-07-01 2025-09-30 0001160420 ADIA:SalesOfBiologicsMember 2026-01-01 2026-09-30 0001160420 ADIA:SalesOfBiologicsMember 2025-01-01 2025-09-30 0001160420 ADIA:ServicesMember 2026-07-01 2026-09-30 0001160420 ADIA:ServicesMember 2025-07-01 2025-09-30 0001160420 ADIA:ServicesMember 2026-01-01 2026-09-30 0001160420 ADIA:ServicesMember 2025-01-01 2025-09-30 0001160420 ADIA:ShippingAndDeliveryMember 2026-07-01 2026-09-30 0001160420 ADIA:ShippingAndDeliveryMember 2025-07-01 2025-09-30 0001160420 ADIA:ShippingAndDeliveryMember 2026-01-01 2026-09-30 0001160420 ADIA:ShippingAndDeliveryMember 2025-01-01 2025-09-30 0001160420 ADIA:SupplementsMember 2026-07-01 2026-09-30 0001160420 ADIA:SupplementsMember 2025-07-01 2025-09-30 0001160420 ADIA:SupplementsMember 2026-01-01 2026-09-30 0001160420 ADIA:SupplementsMember 2025-01-01 2025-09-30 0001160420 ADIA:ProceduresMember 2026-07-01 2026-09-30 0001160420 ADIA:ProceduresMember 2025-07-01 2025-09-30 0001160420 ADIA:ProceduresMember 2026-01-01 2026-09-30 0001160420 ADIA:ProceduresMember 2025-01-01 2025-09-30 0001160420 ADIA:BiologicsMember 2026-07-01 2026-09-30 0001160420 ADIA:BiologicsMember 2025-07-01 2025-09-30 0001160420 ADIA:BiologicsMember 2026-01-01 2026-09-30 0001160420 ADIA:BiologicsMember 2025-01-01 2025-09-30 0001160420 ADIA:Special2022SeriesAPreferredMember 2024-12-31 0001160420 ADIA:SeriesAPreferredMember 2024-12-31 0001160420 ADIA:SeriesCPreferredMember 2024-12-31 0001160420 ADIA:SharesToBeIssuedMember 2024-12-31 0001160420 ADIA:Special2022SeriesAPreferredMember 2025-03-31 0001160420 ADIA:SeriesAPreferredMember 2025-03-31 0001160420 ADIA:SeriesCPreferredMember 2025-03-31 0001160420 ADIA:SharesToBeIssuedMember 2025-03-31 0001160420 ADIA:Special2022SeriesAPreferredMember 2025-06-30 0001160420 ADIA:SeriesAPreferredMember 2025-06-30 0001160420 ADIA:SeriesCPreferredMember 2025-06-30 0001160420 ADIA:SharesToBeIssuedMember 2025-06-30 0001160420 ADIA:ClassACommonStockMember 2024-12-31 0001160420 ADIA:ClassBCommonStockMember 2024-12-31 0001160420 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001160420 us-gaap:RetainedEarningsMember 2024-12-31 0001160420 2024-12-31 0001160420 ADIA:ClassACommonStockMember 2025-03-31 0001160420 ADIA:ClassBCommonStockMember 2025-03-31 0001160420 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001160420 us-gaap:RetainedEarningsMember 2025-03-31 0001160420 2025-03-31 0001160420 ADIA:ClassACommonStockMember 2025-06-30 0001160420 ADIA:ClassBCommonStockMember 2025-06-30 0001160420 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001160420 us-gaap:RetainedEarningsMember 2025-06-30 0001160420 2025-06-30 0001160420 ADIA:Special2022SeriesAPreferredMember 2025-12-31 0001160420 ADIA:SeriesAPreferredMember 2025-12-31 0001160420 ADIA:SeriesCPreferredMember 2025-12-31 0001160420 ADIA:SharesToBeIssuedMember 2025-12-31 0001160420 ADIA:Special2022SeriesAPreferredMember 2026-03-31 0001160420 ADIA:SeriesAPreferredMember 2026-03-31 0001160420 ADIA:SeriesCPreferredMember 2026-03-31 0001160420 ADIA:SharesToBeIssuedMember 2026-03-31 0001160420 ADIA:Special2022SeriesAPreferredMember 2026-06-30 0001160420 ADIA:SeriesAPreferredMember 2026-06-30 0001160420 ADIA:SeriesCPreferredMember 2026-06-30 0001160420 ADIA:SharesToBeIssuedMember 2026-06-30 0001160420 ADIA:ClassACommonStockMember 2025-12-31 0001160420 ADIA:ClassBCommonStockMember 2025-12-31 0001160420 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001160420 us-gaap:RetainedEarningsMember 2025-12-31 0001160420 ADIA:ClassACommonStockMember 2026-03-31 0001160420 ADIA:ClassBCommonStockMember 2026-03-31 0001160420 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001160420 us-gaap:RetainedEarningsMember 2026-03-31 0001160420 2026-03-31 0001160420 ADIA:ClassACommonStockMember 2026-06-30 0001160420 ADIA:ClassBCommonStockMember 2026-06-30 0001160420 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001160420 us-gaap:RetainedEarningsMember 2026-06-30 0001160420 2026-06-30 0001160420 ADIA:Special2022SeriesAPreferredMember 2025-01-01 2025-03-31 0001160420 ADIA:SeriesAPreferredMember 2025-01-01 2025-03-31 0001160420 ADIA:SeriesCPreferredMember 2025-01-01 2025-03-31 0001160420 ADIA:SharesToBeIssuedMember 2025-01-01 2025-03-31 0001160420 ADIA:Special2022SeriesAPreferredMember 2025-04-01 2025-06-30 0001160420 ADIA:SeriesAPreferredMember 2025-04-01 2025-06-30 0001160420 ADIA:SeriesCPreferredMember 2025-04-01 2025-06-30 0001160420 ADIA:SharesToBeIssuedMember 2025-04-01 2025-06-30 0001160420 ADIA:Special2022SeriesAPreferredMember 2025-07-01 2025-09-30 0001160420 ADIA:SeriesAPreferredMember 2025-07-01 2025-09-30 0001160420 ADIA:SeriesCPreferredMember 2025-07-01 2025-09-30 0001160420 ADIA:SharesToBeIssuedMember 2025-07-01 2025-09-30 0001160420 ADIA:ClassACommonStockMember 2025-01-01 2025-03-31 0001160420 ADIA:ClassBCommonStockMember 2025-01-01 2025-03-31 0001160420 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001160420 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001160420 2025-01-01 2025-03-31 0001160420 ADIA:ClassACommonStockMember 2025-04-01 2025-06-30 0001160420 ADIA:ClassBCommonStockMember 2025-04-01 2025-06-30 0001160420 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001160420 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001160420 2025-04-01 2025-06-30 0001160420 ADIA:ClassACommonStockMember 2025-07-01 2025-09-30 0001160420 ADIA:ClassBCommonStockMember 2025-07-01 2025-09-30 0001160420 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001160420 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001160420 ADIA:Special2022SeriesAPreferredMember 2026-01-01 2026-03-31 0001160420 ADIA:SeriesAPreferredMember 2026-01-01 2026-03-31 0001160420 ADIA:SeriesCPreferredMember 2026-01-01 2026-03-31 0001160420 ADIA:SharesToBeIssuedMember 2026-01-01 2026-03-31 0001160420 ADIA:Special2022SeriesAPreferredMember 2026-04-01 2026-06-30 0001160420 ADIA:SeriesAPreferredMember 2026-04-01 2026-06-30 0001160420 ADIA:SeriesCPreferredMember 2026-04-01 2026-06-30 0001160420 ADIA:SharesToBeIssuedMember 2026-04-01 2026-06-30 0001160420 ADIA:Special2022SeriesAPreferredMember 2026-07-01 2026-09-30 0001160420 ADIA:SeriesAPreferredMember 2026-07-01 2026-09-30 0001160420 ADIA:SeriesCPreferredMember 2026-07-01 2026-09-30 0001160420 ADIA:SharesToBeIssuedMember 2026-07-01 2026-09-30 0001160420 ADIA:ClassACommonStockMember 2026-01-01 2026-03-31 0001160420 ADIA:ClassBCommonStockMember 2026-01-01 2026-03-31 0001160420 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001160420 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001160420 2026-01-01 2026-03-31 0001160420 ADIA:ClassACommonStockMember 2026-04-01 2026-06-30 0001160420 ADIA:ClassBCommonStockMember 2026-04-01 2026-06-30 0001160420 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001160420 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001160420 2026-04-01 2026-06-30 0001160420 ADIA:ClassACommonStockMember 2026-07-01 2026-09-30 0001160420 ADIA:ClassBCommonStockMember 2026-07-01 2026-09-30 0001160420 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001160420 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001160420 ADIA:Special2022SeriesAPreferredMember 2025-09-30 0001160420 ADIA:SeriesAPreferredMember 2025-09-30 0001160420 ADIA:SeriesCPreferredMember 2025-09-30 0001160420 ADIA:SharesToBeIssuedMember 2025-09-30 0001160420 ADIA:ClassACommonStockMember 2025-09-30 0001160420 ADIA:ClassBCommonStockMember 2025-09-30 0001160420 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001160420 us-gaap:RetainedEarningsMember 2025-09-30 0001160420 2025-09-30 0001160420 ADIA:Special2022SeriesAPreferredMember 2026-09-30 0001160420 ADIA:SeriesAPreferredMember 2026-09-30 0001160420 ADIA:SeriesCPreferredMember 2026-09-30 0001160420 ADIA:SharesToBeIssuedMember 2026-09-30 0001160420 ADIA:ClassACommonStockMember 2026-09-30 0001160420 ADIA:ClassBCommonStockMember 2026-09-30 0001160420 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001160420 us-gaap:RetainedEarningsMember 2026-09-30 0001160420 us-gaap:SeriesAPreferredStockMember 2022-06-16 2022-06-17 0001160420 ADIA:SharesToBeIssuedMember us-gaap:SeriesCPreferredStockMember ADIA:MonicaSherMember 2024-08-18 2024-08-19 0001160420 ADIA:SharesToBeIssuedMember us-gaap:SeriesCPreferredStockMember ADIA:RichardEdwardsMember 2024-09-09 2024-09-10 0001160420 ADIA:SharesToBeIssuedMember us-gaap:SeriesCPreferredStockMember ADIA:KalpeshBarotMember 2024-09-22 2024-09-23 0001160420 ADIA:SharesToBeIssuedMember us-gaap:SeriesCPreferredStockMember ADIA:EvanThomasMember 2026-07-26 2026-07-27 0001160420 ADIA:CementFactoryLLCMember 2026-01-01 2026-09-30 0001160420 srt:MinimumMember 2026-09-30 0001160420 srt:MaximumMember 2026-09-30 0001160420 srt:ScenarioPreviouslyReportedMember 2026-04-01 2026-06-30 0001160420 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2026-04-01 2026-06-30 0001160420 ADIA:SalesOfSupplementsMember srt:ScenarioPreviouslyReportedMember 2026-04-01 2026-06-30 0001160420 ADIA:SalesOfSupplementsMember srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2026-04-01 2026-06-30 0001160420 ADIA:SalesOfSupplementsMember 2026-04-01 2026-06-30 0001160420 ADIA:MedicalProceduresMember srt:ScenarioPreviouslyReportedMember 2026-04-01 2026-06-30 0001160420 ADIA:MedicalProceduresMember srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2026-04-01 2026-06-30 0001160420 ADIA:MedicalProceduresMember 2026-04-01 2026-06-30 0001160420 ADIA:SalesOfBiologicsMember srt:ScenarioPreviouslyReportedMember 2026-04-01 2026-06-30 0001160420 ADIA:SalesOfBiologicsMember srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2026-04-01 2026-06-30 0001160420 ADIA:SalesOfBiologicsMember 2026-04-01 2026-06-30 0001160420 ADIA:ServicesMember srt:ScenarioPreviouslyReportedMember 2026-04-01 2026-06-30 0001160420 ADIA:ServicesMember srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2026-04-01 2026-06-30 0001160420 ADIA:ServicesMember 2026-04-01 2026-06-30 0001160420 ADIA:ShippingAndDeliveryMember srt:ScenarioPreviouslyReportedMember 2026-04-01 2026-06-30 0001160420 ADIA:ShippingAndDeliveryMember srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2026-04-01 2026-06-30 0001160420 ADIA:ShippingAndDeliveryMember 2026-04-01 2026-06-30 0001160420 ADIA:SupplementsMember srt:ScenarioPreviouslyReportedMember 2026-04-01 2026-06-30 0001160420 ADIA:SupplementsMember srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2026-04-01 2026-06-30 0001160420 ADIA:SupplementsMember 2026-04-01 2026-06-30 0001160420 ADIA:ProceduresMember srt:ScenarioPreviouslyReportedMember 2026-04-01 2026-06-30 0001160420 ADIA:ProceduresMember srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2026-04-01 2026-06-30 0001160420 ADIA:ProceduresMember 2026-04-01 2026-06-30 0001160420 ADIA:BiologicsMember srt:ScenarioPreviouslyReportedMember 2026-04-01 2026-06-30 0001160420 ADIA:BiologicsMember srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2026-04-01 2026-06-30 0001160420 ADIA:BiologicsMember 2026-04-01 2026-06-30 0001160420 srt:ScenarioPreviouslyReportedMember 2026-01-01 2026-06-30 0001160420 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2026-01-01 2026-06-30 0001160420 2026-01-01 2026-06-30 0001160420 ADIA:SalesOfSupplementsMember srt:ScenarioPreviouslyReportedMember 2026-01-01 2026-06-30 0001160420 ADIA:SalesOfSupplementsMember srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2026-01-01 2026-06-30 0001160420 ADIA:SalesOfSupplementsMember 2026-01-01 2026-06-30 0001160420 ADIA:MedicalProceduresMember srt:ScenarioPreviouslyReportedMember 2026-01-01 2026-06-30 0001160420 ADIA:MedicalProceduresMember srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2026-01-01 2026-06-30 0001160420 ADIA:MedicalProceduresMember 2026-01-01 2026-06-30 0001160420 ADIA:SalesOfBiologicsMember srt:ScenarioPreviouslyReportedMember 2026-01-01 2026-06-30 0001160420 ADIA:SalesOfBiologicsMember srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2026-01-01 2026-06-30 0001160420 ADIA:SalesOfBiologicsMember 2026-01-01 2026-06-30 0001160420 ADIA:ServicesMember srt:ScenarioPreviouslyReportedMember 2026-01-01 2026-06-30 0001160420 ADIA:ServicesMember srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2026-01-01 2026-06-30 0001160420 ADIA:ServicesMember 2026-01-01 2026-06-30 0001160420 ADIA:ShippingAndDeliveryMember srt:ScenarioPreviouslyReportedMember 2026-01-01 2026-06-30 0001160420 ADIA:ShippingAndDeliveryMember srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2026-01-01 2026-06-30 0001160420 ADIA:ShippingAndDeliveryMember 2026-01-01 2026-06-30 0001160420 ADIA:SupplementsMember srt:ScenarioPreviouslyReportedMember 2026-01-01 2026-06-30 0001160420 ADIA:SupplementsMember srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2026-01-01 2026-06-30 0001160420 ADIA:SupplementsMember 2026-01-01 2026-06-30 0001160420 ADIA:ProceduresMember srt:ScenarioPreviouslyReportedMember 2026-01-01 2026-06-30 0001160420 ADIA:ProceduresMember srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2026-01-01 2026-06-30 0001160420 ADIA:ProceduresMember 2026-01-01 2026-06-30 0001160420 ADIA:BiologicsMember srt:ScenarioPreviouslyReportedMember 2026-01-01 2026-06-30 0001160420 ADIA:BiologicsMember srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2026-01-01 2026-06-30 0001160420 ADIA:BiologicsMember 2026-01-01 2026-06-30 0001160420 ADIA:SalesOfSupplementsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2026-01-01 2026-09-30 0001160420 ADIA:SalesOfSupplementsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2025-01-01 2025-09-30 0001160420 ADIA:MedicalProceduresMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2026-01-01 2026-09-30 0001160420 ADIA:MedicalProceduresMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2025-01-01 2025-09-30 0001160420 ADIA:SalesOfBiologicsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2026-01-01 2026-09-30 0001160420 ADIA:SalesOfBiologicsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2025-01-01 2025-09-30 0001160420 ADIA:ServicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2026-01-01 2026-09-30 0001160420 ADIA:ServicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2025-01-01 2025-09-30 0001160420 ADIA:ShippingAndDeliveryMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2026-01-01 2026-09-30 0001160420 ADIA:ShippingAndDeliveryMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2025-01-01 2025-09-30 0001160420 ADIA:TotalRevenueMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2026-01-01 2026-09-30 0001160420 ADIA:TotalRevenueMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2025-01-01 2025-09-30 0001160420 ADIA:CostOfSupplementsMember 2026-01-01 2026-09-30 0001160420 ADIA:CostOfSupplementsMember ADIA:CostOfRevenueMember us-gaap:ProductConcentrationRiskMember 2026-01-01 2026-09-30 0001160420 ADIA:CostOfSupplementsMember 2025-01-01 2025-09-30 0001160420 ADIA:CostOfSupplementsMember ADIA:CostOfRevenueMember us-gaap:ProductConcentrationRiskMember 2025-01-01 2025-09-30 0001160420 ADIA:CostForAdministrationOfMedicalProceduresMember 2026-01-01 2026-09-30 0001160420 ADIA:CostForAdministrationOfMedicalProceduresMember ADIA:CostOfRevenueMember us-gaap:ProductConcentrationRiskMember 2026-01-01 2026-09-30 0001160420 ADIA:CostForAdministrationOfMedicalProceduresMember 2025-01-01 2025-09-30 0001160420 ADIA:CostForAdministrationOfMedicalProceduresMember ADIA:CostOfRevenueMember us-gaap:ProductConcentrationRiskMember 2025-01-01 2025-09-30 0001160420 ADIA:CostOfBiologicsMember 2026-01-01 2026-09-30 0001160420 ADIA:CostOfBiologicsMember ADIA:CostOfRevenueMember us-gaap:ProductConcentrationRiskMember 2026-01-01 2026-09-30 0001160420 ADIA:CostOfBiologicsMember 2025-01-01 2025-09-30 0001160420 ADIA:CostOfBiologicsMember ADIA:CostOfRevenueMember us-gaap:ProductConcentrationRiskMember 2025-01-01 2025-09-30 0001160420 ADIA:TotalCostOfRevenueMember ADIA:CostOfRevenueMember us-gaap:ProductConcentrationRiskMember 2026-01-01 2026-09-30 0001160420 ADIA:TotalCostOfRevenueMember ADIA:CostOfRevenueMember us-gaap:ProductConcentrationRiskMember 2025-01-01 2025-09-30 0001160420 2025-01-01 2025-12-31 0001160420 ADIA:BiologicProductsMember 2026-09-30 0001160420 ADIA:BiologicProductsMember 2025-12-31 0001160420 us-gaap:FurnitureAndFixturesMember 2026-09-30 0001160420 us-gaap:FurnitureAndFixturesMember 2025-12-31 0001160420 us-gaap:MachineryAndEquipmentMember 2026-09-30 0001160420 us-gaap:MachineryAndEquipmentMember 2025-12-31 0001160420 ADIA:QCMBiologicsMembershipMember 2026-09-30 0001160420 ADIA:QCMBiologicsMembershipMember 2026-01-01 2026-09-30 0001160420 ADIA:QCMBiologicsMembershipMember 2025-12-31 0001160420 ADIA:BioleteLLCMember 2024-07-11 0001160420 ADIA:BioleteLLCMember 2024-07-10 2024-07-11 0001160420 ADIA:BioleteMember 2025-09-30 0001160420 ADIA:CementFactoryMember ADIA:BioleteInventoryMember 2025-09-30 0001160420 ADIA:CementFactoryMember ADIA:BioleteTrademarksMember 2025-09-30 0001160420 ADIA:CementFactoryMember ADIA:BioleteWebsiteMember 2025-09-30 0001160420 ADIA:CementFactoryMember 2025-09-30 0001160420 ADIA:CementFactoryMember 2026-01-01 2026-09-30 0001160420 ADIA:CementFactoryMember 2025-01-01 2025-12-31 0001160420 ADIA:CementFactoryMember 2026-09-30 0001160420 ADIA:CementFactoryMember 2025-12-31 0001160420 srt:ChiefExecutiveOfficerMember 2026-09-30 0001160420 srt:ChiefExecutiveOfficerMember 2026-01-01 2026-09-30 0001160420 srt:ChiefExecutiveOfficerMember 2025-01-01 2025-12-31 0001160420 srt:ChiefExecutiveOfficerMember 2025-12-31 0001160420 srt:ChiefExecutiveOfficerMember ADIA:CEOCreditLineMember 2026-07-01 2026-09-30 0001160420 srt:ChiefExecutiveOfficerMember ADIA:CEOCreditLineMember 2025-07-01 2025-09-30 0001160420 srt:ChiefExecutiveOfficerMember ADIA:CEOCreditLineMember 2026-01-01 2026-09-30 0001160420 srt:ChiefExecutiveOfficerMember ADIA:CEOCreditLineMember 2025-01-01 2025-09-30 0001160420 srt:ChiefExecutiveOfficerMember ADIA:CEOCreditLineMember 2026-09-30 0001160420 srt:ChiefExecutiveOfficerMember ADIA:CEOCreditLineMember 2025-12-31 0001160420 ADIA:AspireRegenerativeTherapyMember 2025-07-15 0001160420 ADIA:AspireRegenerativeTherapyMember 2025-12-31 0001160420 ADIA:AspireRegenerativeTherapyMember 2026-09-30 0001160420 ADIA:AspireRegenerativeTherapyMember 2026-07-01 2026-09-30 0001160420 ADIA:AspireRegenerativeTherapyMember 2025-07-01 2025-09-30 0001160420 ADIA:AspireRegenerativeTherapyMember 2026-01-01 2026-09-30 0001160420 ADIA:AspireRegenerativeTherapyMember 2025-01-01 2025-09-30 0001160420 ADIA:GAIPMember 2026-04-06 0001160420 ADIA:GAIPMember 2026-07-01 2026-09-30 0001160420 ADIA:GAIPMember 2026-01-01 2026-09-30 0001160420 ADIA:GAIPMember 2025-07-01 2025-09-30 0001160420 ADIA:GAIPMember 2025-01-01 2025-09-30 0001160420 ADIA:GAIPMember 2026-09-30 0001160420 ADIA:MembershipInterestPurchaseAgreeementMember ADIA:AdiaLabsLLCInvestmentMember 2026-09-30 0001160420 ADIA:MembershipInterestPurchaseAgreeementMember ADIA:AdiaLabsLLCInvestmentMember 2026-01-01 2026-09-30 0001160420 us-gaap:CommonStockMember 2026-09-30 0001160420 ADIA:RegulationAFilingMember 2024-07-08 2024-07-09 0001160420 us-gaap:CommonStockMember 2025-05-04 2025-05-05 0001160420 ADIA:RegulationAFilingMember 2025-06-05 2025-06-06 0001160420 ADIA:RegulationAFilingMember 2025-06-10 2025-06-11 0001160420 us-gaap:CommonClassAMember 2026-09-30 0001160420 us-gaap:CommonClassAMember 2025-12-31 0001160420 us-gaap:CommonClassBMember 2026-09-30 0001160420 us-gaap:CommonClassBMember 2025-12-31 0001160420 us-gaap:PreferredStockMember 2026-09-30 0001160420 ADIA:Special2022SeriesAPreferredStockMember 2026-09-30 0001160420 ADIA:CementFactoryNutritionMember us-gaap:SeriesCPreferredStockMember 2024-07-28 2024-07-29 0001160420 ADIA:SharesToBeIssuedMember us-gaap:SeriesCPreferredStockMember ADIA:EvanThomasMember 2025-10-12 2025-10-13 0001160420 us-gaap:SeriesCPreferredStockMember ADIA:TwoOfficersMember 2025-01-01 2025-12-31 0001160420 ADIA:Special2022SeriesAPreferredStockMember 2025-12-31 0001160420 ADIA:AdiaMedAssetsMember 2026-09-30 0001160420 ADIA:AdiaMedAssetsMember 2025-12-31 0001160420 ADIA:AdiaLabsAssetsMember 2026-09-30 0001160420 ADIA:AdiaLabsAssetsMember 2025-12-31 0001160420 ADIA:UnallocatedCorporateAssetsMember 2026-09-30 0001160420 ADIA:UnallocatedCorporateAssetsMember 2025-12-31 0001160420 us-gaap:CorporateAndOtherMember 2026-01-01 2026-09-30 0001160420 ADIA:BioleteMember 2026-01-01 2026-09-30 0001160420 ADIA:AdiaMedMember 2026-01-01 2026-09-30 0001160420 ADIA:AdiaLabsMember 2026-01-01 2026-09-30 0001160420 us-gaap:CorporateAndOtherMember ADIA:MedicalProceduresMember 2026-01-01 2026-09-30 0001160420 ADIA:BioleteMember ADIA:MedicalProceduresMember 2026-01-01 2026-09-30 0001160420 ADIA:AdiaMedMember ADIA:MedicalProceduresMember 2026-01-01 2026-09-30 0001160420 ADIA:AdiaLabsMember ADIA:MedicalProceduresMember 2026-01-01 2026-09-30 0001160420 us-gaap:CorporateAndOtherMember ADIA:SalesOfBiologicsNetOfDiscountsAndRefundsMember 2026-01-01 2026-09-30 0001160420 ADIA:BioleteMember ADIA:SalesOfBiologicsNetOfDiscountsAndRefundsMember 2026-01-01 2026-09-30 0001160420 ADIA:AdiaMedMember ADIA:SalesOfBiologicsNetOfDiscountsAndRefundsMember 2026-01-01 2026-09-30 0001160420 ADIA:AdiaLabsMember ADIA:SalesOfBiologicsNetOfDiscountsAndRefundsMember 2026-01-01 2026-09-30 0001160420 ADIA:SalesOfBiologicsNetOfDiscountsAndRefundsMember 2026-01-01 2026-09-30 0001160420 us-gaap:CorporateAndOtherMember ADIA:ShippingAndDeliveryMember 2026-01-01 2026-09-30 0001160420 ADIA:BioleteMember ADIA:ShippingAndDeliveryMember 2026-01-01 2026-09-30 0001160420 ADIA:AdiaMedMember ADIA:ShippingAndDeliveryMember 2026-01-01 2026-09-30 0001160420 ADIA:AdiaLabsMember ADIA:ShippingAndDeliveryMember 2026-01-01 2026-09-30 0001160420 us-gaap:CorporateAndOtherMember 2025-01-01 2025-09-30 0001160420 ADIA:BioleteMember 2025-01-01 2025-09-30 0001160420 ADIA:AdiaMedMember 2025-01-01 2025-09-30 0001160420 ADIA:AdiaLabsMember 2025-01-01 2025-09-30 0001160420 us-gaap:CorporateAndOtherMember ADIA:MedicalProceduresMember 2025-01-01 2025-09-30 0001160420 ADIA:BioleteMember ADIA:MedicalProceduresMember 2025-01-01 2025-09-30 0001160420 ADIA:AdiaMedMember ADIA:MedicalProceduresMember 2025-01-01 2025-09-30 0001160420 ADIA:AdiaLabsMember ADIA:MedicalProceduresMember 2025-01-01 2025-09-30 0001160420 us-gaap:CorporateAndOtherMember ADIA:SalesOfBiologicsNetOfDiscountsAndRefundsMember 2025-01-01 2025-09-30 0001160420 ADIA:BioleteMember ADIA:SalesOfBiologicsNetOfDiscountsAndRefundsMember 2025-01-01 2025-09-30 0001160420 ADIA:AdiaMedMember ADIA:SalesOfBiologicsNetOfDiscountsAndRefundsMember 2025-01-01 2025-09-30 0001160420 ADIA:AdiaLabsMember ADIA:SalesOfBiologicsNetOfDiscountsAndRefundsMember 2025-01-01 2025-09-30 0001160420 ADIA:SalesOfBiologicsNetOfDiscountsAndRefundsMember 2025-01-01 2025-09-30 0001160420 us-gaap:CorporateAndOtherMember ADIA:SalesOfSupplementsMember 2025-01-01 2025-09-30 0001160420 ADIA:BioleteMember ADIA:SalesOfSupplementsMember 2025-01-01 2025-09-30 0001160420 ADIA:AdiaMedMember ADIA:SalesOfSupplementsMember 2025-01-01 2025-09-30 0001160420 ADIA:AdiaLabsMember ADIA:SalesOfSupplementsMember 2025-01-01 2025-09-30 0001160420 us-gaap:CorporateAndOtherMember us-gaap:ServiceMember 2025-01-01 2025-09-30 0001160420 ADIA:BioleteMember us-gaap:ServiceMember 2025-01-01 2025-09-30 0001160420 ADIA:AdiaMedMember us-gaap:ServiceMember 2025-01-01 2025-09-30 0001160420 ADIA:AdiaLabsMember us-gaap:ServiceMember 2025-01-01 2025-09-30 0001160420 us-gaap:ServiceMember 2025-01-01 2025-09-30 0001160420 us-gaap:CorporateAndOtherMember ADIA:ShippingAndDeliveryMember 2025-01-01 2025-09-30 0001160420 ADIA:BioleteMember ADIA:ShippingAndDeliveryMember 2025-01-01 2025-09-30 0001160420 ADIA:AdiaMedMember ADIA:ShippingAndDeliveryMember 2025-01-01 2025-09-30 0001160420 ADIA:AdiaLabsMember ADIA:ShippingAndDeliveryMember 2025-01-01 2025-09-30 0001160420 us-gaap:SeriesAPreferredStockMember 2025-05-04 2025-05-05 0001160420 us-gaap:CommonStockMember 2024-05-31 0001160420 us-gaap:CommonStockMember ADIA:LotusMember 2024-05-31 0001160420 us-gaap:CommonStockMember ADIA:CoombsMember 2024-05-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure ADIA:Integer

Table of Contents

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2026

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ______________

 

Commission file number: 000-33265

 

ADIA MED, INC.

(Exact name of registrant as specified in its charter)

 

Nevada

 

35-2829671

(State or other jurisdiction
of incorporation or organization)
  (I.R.S. Employer
Identification Number)

 

4421 Gabriella Lane

Winter Park, FL

 

32792

(Address of principal executive offices)   Zip Code

 

Registrant’s telephone number: (321) 231-2843

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

N/A   N/A   N/A

 

Securities to be registered pursuant to Section 12(g) of the Act: None

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
  Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

  

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

As of November 16, 2026, there were 94,404,696 shares of common stock, par value $0.001 per share, of the registrant issued and outstanding.

 

 

 

   

 

 

Table of Contents

 

    Page
Part I—Financial Information  
     
Item 1. Financial Statements 4
  Condensed Consolidated Balance Sheets at September 30, 2026 (Unaudited) and December 31, 2025 5
  Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2026 and 2025 (Unaudited) 6
  Condensed Consolidated Statements of Stockholders’ Deficit for the Three and Nine Months Ended September 30, 2026, and 2025 (Unaudited) 7
  Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2026 and 2025 (Unaudited) 8
  Notes to Unaudited Condensed Consolidated Financial Statements 9
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 34
Item 3. Quantitative and Qualitative Disclosures About Market Risk 49
Item 4. Controls and Procedures 49
     
Part II—Other Information  
     
Item 1. Legal Proceedings 51
Item 1A. Risk Factors 52
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 52
Item 3. Defaults Upon Senior Securities 52
Item 4. Mine Safety Disclosures 52
Item 5. Other Information 52
Item 6. Exhibits 53
     
  Signatures 54

 

 

 

 

 

 2 

 

 

CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS

 

This Quarterly Report includes “forward-looking statements” within the meaning of the federal securities laws that involve risks and uncertainties. Forward-looking statements include statements we make concerning our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. When used in this quarterly report, the words “estimates,” “expects,” “anticipates,” “projects,” “forecasts,” “plans,” “intends,” “believes,” “foresees,” “seeks,” “likely,” “may,” “might,” “will,” “should,” “goal,” “target” or “intends” and variations of these words or similar expressions (or the negative versions of any such words) are intended to identify forward-looking statements. All forward-looking statements are based upon information available to us on the date of this Quarterly Report.

 

These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. These risks and uncertainties are discussed in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 31, 2026, as the same may be updated from time to time.

 

All forward-looking statements attributable to us in this Quarterly Report apply only as of the date of this Quarterly Report and are expressly qualified in their entirety by the cautionary statements included in this Quarterly Report. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect events or circumstances after the date made or to reflect the occurrence of unanticipated events, except as required by law.

 

 

 

 

 

 

 3 

 

 

PART I—FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

ADIA Med, Inc. and Subsidiaries

 

    Page(s)
     
Condensed Consolidated Balance Sheets (Unaudited)   5
     
Condensed Consolidated Statements of Operations (Unaudited)   6
     
Condensed Consolidated Statements of Stockholders’ Deficit (Unaudited)   7
     
Condensed Consolidated Statements of Cash Flows (Unaudited)   9
     
Notes to the Unaudited Condensed Consolidated Financial Statements   10 - 33

 

 

 

 

 

 

 4 

 

 

ADIA MED, INC.

(Formerly known as Adia Nutrition, Inc.)

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

         
   September 30,   December 31, 
   2026   2025 
ASSETS          
Current Assets          
Cash  $1,137,818   $79,392 
Undeposited funds   4,900    – 
Accounts receivable   53,360    33,360 
Accrued interest due   750    250 
Inventory          
Inventory on-hand          
Biologics   78,500    25,025 
Pre-paid inventory   270,000    – 
Prepaid expenses   18,286    23,483 
Total Current Assets   1,563,614    161,510 
           
Investment in non-consolidated entity   79,500    79,500 
Receivable on sale of inventory asset   71,731    72,107 
Loans to clinics   30,300    25,000 
Deposits   10,000    10,000 
Note receivable on investment   500,000    – 
Fixed assets, net of depreciation   41,790    30,695 
Finance lease, net   90,424    108,171 
Right of use asset - operating lease, net   65,628    107,843 
Total Non-Current Assets   889,373    433,316 
Total Assets  $2,452,987   $594,826 
           
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)          
           
Current Liabilities          
Accounts payable  $22,805   $2,393 
Accounts payable - related party   170,000    – 
Payroll liabilities   153    153 
Accrued interest – related party   74,672    37,915 
Deferred revenue   140,300    14,000 
Line of credit - related party   935,312    600,000 
Lease liability – current portion          
Operating   65,219    63,950 
Finance   26,784    26,784 
Total Current Liabilities   1,435,245    745,195 
           
Long-term lease liabilities, net of current portion          
Operating   2,448    45,918 
Finance   44,890    61,387 
Total Non-Current Liabilities   47,338    107,305 
Total Liabilities   1,482,583    852,500 
           

Commitments and Contingencies (Note 15)

   –    – 
           
Stockholders' Equity (Deficit)          
Special 2022 Series A Preferred Stock, $0.001 par value, 1 share authorized, issued and outstanding at September 30, 2026 and December 31, 2025.   1    1 
Series A Preferred Stock, $0.001 par value, 10,000,000 shares authorized, zero issued and outstanding at September 30, 2026 and December 31, 2025.   –    – 
Series C Preferred Stock, $0.001 par value, 89,999,999 shares authorized, 4,375,000 and 1,750,000 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively.   4,375    1,750 
Class A Common Stock, $0.001 par value; 800,000,000 shares authorized, 94,404,696  shares issued and outstanding, at September 30, 2026 and December 31, 2025.   94,405    94,405 
Class B Common Stock, $0.001 par value; 100,000,000 shares authorized, zero issued and outstanding, at September 30, 2026 and December 31, 2025.   –    – 
Shares to be issued   42,250    152,607 
Additional paid-in capital   17,074,777    15,467,045 
Accumulated deficit   (16,245,404)   (15,973,482)
Total Stockholders' Equity (Deficit)   970,404    (257,674)
           
Total Liabilities and Stockholders’ Equity (Deficit)  $2,452,987   $594,826 

 

See accompanying notes to unaudited condensed consolidated financial statements

 

 

 5 

 

 

ADIA MED, INC.

(Formerly known as Adia Nutrition, Inc.)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

                 
  

For the Three Months Ended

September 30,

  

For the Nine Months Ended

September 30,

 
   2026   2025   2026   2025 
Revenue                    
Sales of supplements  $–   $1,238   $–   $3,393 
Medical procedures   238,900    101,900    576,770    198,600 
Sales of biologics   211,735    225,510    433,260    313,010 
Services   –    –    –    2,267 
Shipping and delivery   3,750    3,400    9,215    4,688 
Total Revenue   454,385    332,048    1,019,245    521,958 
                     
Cost of Revenue                    
Supplements   –    395    –    1,057 
Procedures   7,124    22,528    160,674    93,315 
Biologics   226,280    105,640    384,233    184,125 
Total Cost of Revenue   233,404    128,563    544,907    278,497 
                     
Gross Profit   220,981    203,485    474,338    243,461 
                     
Operating Expenses                    
General and administrative   33,234    56,707    90,187    129,119 
Advertising and promotion   16,400    23,794    75,843    54,979 
Clinical trial fees   4,250    –    16,275    – 
Corporate filing fees   5,571    –    17,299    – 
Equipment leases   7,946    8,928    21,338    20,088 
Legal and professional fees   75,592    11,162    236,323    104,976 
Public relations   2,400    –    7,320    – 
Repairs and maintenance   476    –    2,638    – 
Rent   16,818    16,240    52,749    48,242 
Research and development   4,375    6,192    4,375    30,808 
Salaries and wages   89,532    –    177,263    – 
Utilities   1,890    –    4,428    – 
Depreciation and amortization   1,647    1,262    4,341    3,178 
Total Operating Expenses   260,131    124,285    710,379    391,390 
                     
Income (Loss) from Operations   (39,150)   79,200    (236,041)   (147,929)
                     
Other Income (Expense)                    
Interest income   125    250    875    250 
Interest expense – related party   (13,990)   (9,074)   (36,756)   (22,160)
Total Other Income (Expense)   (13,865)   (8,824)   (35,881)   (21,910)
                     
Net Income (Loss) Before provision for Income Taxes   (53,015)   70,376    (271,922)   (169,839)
                     
Provision for Income Taxes   –    –    –    – 
                     
NET INCOME (LOSS)  $(53,015)  $70,376   $(271,922)  $(169,839)
                     
Net Income (Loss) Per Share: Basic  $(0.00)  $0.00   $(0.00)  $(0.00)
Net Income (Loss) Per Share: Diluted  $(0.00)  $0.00   $(0.00)  $(0.00)
                     
Weighted Average Number of Shares Outstanding: Basic   94,404,696    91,173,927    94,404,696    91,071,609 
Weighted Average Number of Shares Outstanding: Diluted   94,404,696    158,173,927    94,404,696    91,071,609 

 

See accompanying notes to unaudited condensed consolidated financial statements

 

 6 

 

 

ADIA MED, INC.

(Formerly known as Adia Nutrition, Inc.)

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

(Unaudited)

 

For the Three and Nine Months Ended September 30, 2026 and 2025

                                 
   Special 2022 Series A Preferred   Series A Preferred   Series C Preferred   Shares to be issued 
   Shares   Amount ($)   Shares   Amount ($)   Shares   Amount ($)   Shares   Amount ($) 
Balance December 31, 2024   1    1    10,000,000    10,000    1,750,000    1,750    2,625,000    110,357 
                                         
Net loss   –    –    –    –    –    –    –    – 
Balance March 31, 2025   1    1    10,000,000    10,000    1,750,000    1,750    2,625,000    110,357 
                                         
Cancellation of shares via court order   –    –    (10,000,000)   (10,000)   –    –    –    – 
Shares to be issued for subscriptions – common stock   –    –    –    –    –    –    14,000,000    14,000 
Net loss   –    –    –    –    –    –    –    – 
Balance June 30, 2025   1    1    –    –    1,750,000    1,750    16,625,000    124,357 
                                         
Shares issued for subscriptions – common stock   –    –    –    –    –    –    (14,000,000)   (14,000)
Net loss   –    –    –    –    –    –    –    – 
Balance September 30, 2025   1    1    –    –    1,750,000    1,750    2,625,000    110,357 

(continued)

 

                             
   Class A Common Stock   Class B Common Stock   Additional Paid-In   Accumulated  

Total

Stockholders’

Equity

 
   Shares   Amount ($)   Shares   Amount ($)   Capital ($)   Deficit ($)   (Deficit) ($) 
Balance December 31, 2024   95,899,861    95,900    –    –    15,385,550    (15,578,018)   25,540 
                                    
Net loss   –    –    –    –    –    (116,219)   (116,219)
Balance March 31, 2025   95,899,861    95,900    –    –    15,385,550    (15,694,237)   (90,679)
                                    
Cancellation of shares via court order   (15,495,165)   (15,495)   –    –    25,495    –    – 
Shares to be issued for subscriptions – common stock   –    –    –    –    56,000    –    70,000 
Net loss   –    –    –    –    –    (123,997)   (123,997)
Balance June 30, 2025   80,404,696    80,405    –    –    15,467,045    (15,818,234)   (144,676)
                                    
Shares issued for subscriptions – common stock   14,000,000    14,000    –    –    –    –    – 
Net loss   –    –    –    –    –    70,376    70,376 
Balance September 30, 2025   94,404,696    94,405    –    –    15,467,045    (15,747,859)   (74,301)

 

 

 

 7 

 

 

ADIA MED, INC.

(Formerly known as Adia Nutrition, Inc.)

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

(Unaudited)

 

For the Three and Nine Months Ended September 30, 2026 and 2025

(continued)

 

                                 
   Special 2022 Series A Preferred   Series A Preferred   Series C Preferred   Shares to be issued 
   Shares   Amount ($)   Shares   Amount ($)   Shares   Amount ($)   Shares   Amount ($) 
Balance December 31, 2025   1    1    –    –    1,750,000    1,750    2,875,000    152,607 
                                         
Net loss   –    –    –    –    –    –    –    – 
Balance March 31, 2026   1    1    –    –    1,750,000    1,750    2,875,000    152,607 
                                         
Net loss   –    –    –    –    –    –    –    – 
Balance June 30, 2026   1    1    –    –    1,750,000    1,750    2,875,000    152,607 
                                         
Issuance of preferred shares to directors                       750,000    750    (750,000)   (30,857)
Issuance of preferred shares for investment   –    –    –    –    1,875,000    1,875    (1,875,000)   (79,500)
Sale of membership interest in subsidiary   –    –    –    –    –    –    –    – 
Net loss   –    –    –    –    –    –    –    – 
Balance September 30, 2026   1    1    –    –    4,375,000    4,375    250,000    42,250 

(continued)

 

                             
   Class A Common Stock   Class B Common Stock   Additional Paid-In   Accumulated  

Total

Stockholders’

Equity

 
   Shares   Amount ($)   Shares   Amount ($)   Capital ($)   Deficit ($)   (Deficit) ($) 
Balance December 31, 2025   94,404,696    94,405    –    –    15,467,045    (15,973,482)   (257,674)
                                    
Net loss   –    –    –    –    –    (162,525)   (162,525)
Balance March 31, 2026   94,404,696    94,405    –    –    15,467,045    (16,136,007)   (420,199)
                                    
Net loss   –    –    –    –    –    (56,382)   (56,382)
Balance June 30, 2026   94,404,696    94,405    –    –    15,467,045    (16,192,389)   (476,581)
                                    
Issuance of preferred shares to directors   –    –    –    –    30,107    –    – 
Issuance of preferred shares for acquisition   –    –    –    –    77,625    –    – 
Sale of membership interest in subsidiary   –    –    –    –    1,500,000    –    1,500,000 
Net loss   –    –    –    –    –    (53,015)   (53,015)
Balance September 30, 2026   94,404,696    94,405    –    –    17,074,777    (16,245,404)   970,404)

 

See accompanying notes to unaudited condensed consolidated financial statements

 

 

 

 8 

 

 

ADIA MED, INC.

(Formerly known as Adia Nutrition, Inc.)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

         
  

For the Nine Months Ended

September 30,

 
   2026   2025 
Cash Flows From Operating Activities:          
Net Loss  $(271,922)  $(169,839)
Adjustments to reconcile net loss to net cash used in operations          
Depreciation and amortization   4,341    3,178 
Amortization of right of use asset - operating   42,215    39,075 
Amortization of right-of-use asset - financing   17,747    12,683 
Changes in operating assets and liabilities:          
Accounts receivable   (20,500)   (105,721)
Receivable on sale of inventory asset   376    – 
Prepaid expenses   5,197    25,667 
Inventory   (323,475)   99,168 
Undeposited funds   (4,900)   – 
Accounts payable   190,412    (2,351)
Accrued interest – line of credit   36,757    22,159 
Deferred revenue   126,300    – 
Lease liability - operating   (42,201)   (32,540)
Net Cash Used for Operating Activities   (239,653)   (108,521)
           
Cash Flows From Investing Activities:          
Purchase of furniture & equipment   (15,436)   (13,199)
Loans to clinics   (5,300)   (25,000)
Disposition of intangible assets   –    5,611 
Net Used for Investing Activities   (20,736)   (32,588)
           
Cash Flows From Financing Activities:          
Payments made on lease liability - finance   (16,497)   (12,683)
Proceeds from sale of common stock   –    70,000 
Proceeds from the sale of membership interest in subsidiary   1,000,000    – 
Draws on line of credit - related party   462,812    231,471 
Repayment of line of credit - related party   (127,500)   – 
Net Cash Provided by Financing Activities   1,318,815    288,788 
           
Net Increase in Cash   1,058,426    147,679 
           
Cash at Beginning of Year   79,392    6,323 
           
Cash at End of Period  $1,137,818   $154,002 
           
Supplemental disclosure of cash flow information:          
Cash paid for interest  $–   $– 
Cash paid for taxes  $–   $– 
           
Supplemental disclosure of non-cash investing and financing activities:          
Note receivable on sale of membership interest in subsidiary  $500,000    – 
Shares to be issued for investment in non-consolidated business entity  $–   $79,500 
Shares issued for investment in non-consolidated business entity  $79,500   $– 
Shares issued to directors  $30,875   $– 
Cancellation of shares  $–   $25,495 

 

See accompanying notes to unaudited condensed consolidated financial statements

 

 

 

 9 

 

 

ADIA MED, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2026

 

 

NOTE 1 – ORGANIZATION AND BUSINESS

 

ADIA Med, Inc. (the “Company,” “we,” “us” or “our”), a Nevada corporation, has a calendar fiscal year and is listed on OTC Markets under the trading symbol ADIA. The Company had abandoned its business and failed to take steps to dissolve, liquidate and distribute its assets. It had also failed to meet the required reporting requirements with the Nevada Secretary of State, hold an annual meeting of stockholders and pay its annual franchise tax from 2013 to 2022 which resulted in its Nevada charter being revoked. The Company also failed to provide adequate current public information as defined in Rule 144, promulgated under the Securities Act of 1933, and was thus subject to revocation by the Securities and Exchange Commission pursuant to Section 12(k) of the Exchange Act. In March 2022, a shareholder filed a petition for custodianship with the District Court, Clark County, Nevada and was appointed as the custodian of the Company in June 2022. The Company’s Nevada charter was reinstated on June 27, 2022, and all required reports were filed with the State of Nevada soon thereafter. The custodian was not able to recover any of the Company’s accounting records from previous management but was able to get the shareholder information hence the Company’s outstanding common shares were reflected in the stockholders’ equity section of the unaudited financial statements for the year ended December 31, 2022.

 

The Company was incorporated in the State of Nevada in April 1975 as Domi Associates, Inc. In March 2001, the issuer amended its Articles of Incorporation to change its name to Drilling, Inc. On April 20, 2004, an amendment to the Articles of Incorporation was made to change the name to PIVX Solutions, Inc. In 2012, the issuer changed to ADIA Nutrition, Inc.

 

On March 14, 2022, UMA LLC, a shareholder of the Company, made a demand to the Company, at the last address of record, to comply with the Nevada Secretary of State statues N.R.S. 78.710 and N.R.S. 78.150. UMA, LLC, made several attempts to locate prior management and reinstate the Company’s Nevada charter, which had been revoked. On, May 6, 2022, UMA, LLC filed a petition against the Company in the District Court of Clark County, Nevada, entitled “In the Matter of ADIA Nutrition Inc., a Nevada corporation”, case number A-22-852241-C, along with an Application for Appointment of Custodian.

 

On June 17, 2022, the District Court of Clark County, Nevada entered an Order Granting Application for Appointment of UMA LLC, (the “Order”), as Custodian of the Company. Pursuant to the Order, the UMA LLC (the “Custodian”) has the authority to take any actions on behalf of the Company, which are reasonable, prudent or for the benefit pursuant to, including, but not limited to, issuing shares of stock, and issuing new classes of stock, as well as entering in contracts on behalf of the Company. In addition, the Custodian, pursuant to the Order, is required to meet the requirements under the Nevada charter.

 

On June 17, 2022, the Custodian appointed Nikki Lee as the Company’s sole officer and director. The Custodian designated one share of preferred stock as Special 2022 Series A Preferred Stock at par value $0.001. The Special 2022 Series A Preferred stock has 60% voting rights over all classes of stock and is convertible into sixty million shares of the Company’s common stock. On June 17, 2022, the Custodian granted to itself, one share of Special Series A Preferred Stock.

 

On June 27, 2022, the Company filed a Certificate of Revival with the Secretary State of the State of Nevada, which reinstated the Company’s charter and appointed a new Resident Agent in Nevada.

 

 

 

 10 

 

 

On August 5, 2022, in a private transaction, the Custodian entered into a Securities Purchase Agreement (the “SPA”) with Nairobi Anderson, to sell the Special 2022 Series A Preferred stock, and upon closing, Nairobi Anderson acquired 60% voting control of the Company.

 

On February 27, 2023, Nairobi Anderson entered into an SPA with The Leonard and Elizabeth Greene Family Trust to sell its share of Special 2022 Series A Preferred stock.

 

On January 22, 2024, The Leonard and Elizabeth Greene Family Trust sold its Special 2022 Series A Preferred share to Legends Investments Properties, LLC, 100% owned by Larry Powalisz. Leonard Greene resigned as Director and Larry Powalisz was appointed Chief Executive Officer and Director, and Rebecca Miller was appointed as Chief Financial Officer.

 

On June 2, 2026, the Company filed a Certificate of Amendment with the Secretary of State of the State of Nevada to amend its corporate name from Adia Nutrition, Inc. to Adia Med, Inc. In connection with this name change, our board of directors also filed a Certificate of Amendment for the Company’s Amended and Restated Articles of Incorporation to change its corporate name within its Articles of Incorporation to reflect the corporate name Adia Med, Inc. Subsequently, the Company submitted all required documentation to FINRA and its transfer agent, and received final approval from FINRA regarding the name change on July 10, 2026.

 

ADIA – Going Forward

 

ADIA is dedicated to revolutionizing healthcare through innovative partnerships. The primary focus is to work closely with healthcare providers and health insurance companies to facilitate and provide Autologous Hematopoietic Stem Cell Transplantation (AHSCT) treatments for Multiple Sclerosis (MS) patients.

 

ADIA engages with health insurance companies to advocate for the inclusion and reimbursement of AHSCT treatments for MS patients. The dedicated team navigates the complexities of insurance processes, striving to make these transformative therapies financially accessible to a wider population.

 

ADIA envisions a future where AHSCT is a widely accessible and transformative treatment option for MS patients. Through commitment, collaboration, advocacy, and quality care, the Company aims to redefine the standard of treatment for MS and contribute to improved outcomes and quality of life for those affected by the disease.

 

ADIA is also committed to revolutionizing the supplement industry through strategic acquisitions and investments in companies that uphold the highest standards of integrity and quality. The mission is to empower individuals worldwide to prioritize their health and well-being by providing access to premium supplements crafted exclusively from organic ingredients. ADIA has, during the third quarter of 2024, acquired Biolete, LLC (see Note 7 below) and taken an 18% equity position in Cement Factory, LLC (see Note 8 below).

 

On September 30, 2025, ADIA sold the inventory on hand and the associated trademarks of the Biolete brand to Cement Factory in which is continued to hold its 18% membership interest.

 

Being dedicated to revolutionizing healthcare through innovative partnerships. The primary focus is to work closely with healthcare providers and health insurance companies to facilitate and provide AHSCT treatments for MS patients. In late 2024, ADIA formed Adia Med of Winter Park, LLC as the clinic to perform the aforementioned treatments, and Adia Labs, LLC which will procure and sell the products relating to these procedures.

 

ADIA strives to cultivate a portfolio of brands that exemplify excellence, transparency, and sustainability, ensuring that every product that it offers contributes to the enhancement of the consumers lives.

 

 

 

 11 

 

 

ADIA Med, Inc. – Board of Directors Expansion

 

On August 19, 2024, the Company appointed Monica Sher, MD as a Director of Company. The Company issued 250,000 shares of its Series C Preferred Stock to the Director on July 27, 2026.

 

On September 10, 2024, the Company appointed Richard Edwards, DO as a Director of Company. The Company issued 250,000 shares of its Series C Preferred Stock to the Director on July 27, 2026.

 

On September 23, 2024, the Company appointed Kalpesh Barot, MD as a Director of Company. The Company will issue 250,000 shares of its Series C Preferred Stock at a future date.

 

On October 13, 2025, the Company appointed Dr. Evan Thomas, MD, PhD. as an Independent Medical Director for the Company’s medical division, Adia Med. The Company issued 250,000 shares of its Series C Preferred Stock to the Director on July 27, 2026.

 

NOTE 2 – GOING CONCERN

 

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company generated revenues of $1,019,245 for the nine months ended September 30, 2026, with an associated net loss of $271,922, and at September 30, 2026, the Company has an accumulated deficit of $16,245,404 and working capital of $128,369. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time. The Company’s continuation as a going concern for one year after this quarterly report for the period ended September 30, 2026, is dependent upon, among other things, its ability to generate greater revenues and its ability to obtain capital from third parties. No assurance can be given that the Company will be successful in these efforts.

 

Management anticipates continued growth in revenue and plans to utilize the funding resources it has available (i.e., its line of credit facility) as well as the continued identification of adequate sources of funding to provide bridge capital, financing of receivables, and operating capital for continued growth.

 

The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The Company’s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Management further acknowledges that it is solely responsible for adopting sound accounting practices, establishing and maintaining a system of internal accounting control and preventing and detecting fraud. The Company's system of internal accounting control is designed to assure, among other items, that (1) recorded transactions are valid; (2) valid transactions are recorded; and (3) transactions are recorded in the proper period in a timely manner to produce consolidated financial statements which present fairly the financial condition, results of operations and cash flows of the Company for the respective periods being presented.

 

 

 

 12 

 

 

Use of Estimates

 

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the condensed consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Revision of Previously Issued Financials

 

In connection with the preparation of the Company’s financial statements for the three and nine months ended September 30, 2026, management identified an immaterial error in the previously issued financial statements for the three and six months ending June 30, 2026.

 

Management evaluated the error under SAB Topic 1.M (SAB 99) and SAB Topic 1.N (SAB 108) and concluded that the error was not material to the previously issued financial statements. Accordingly, the Company has revised the financial statements for the three and six months ended June 30, 2026, presented herein to correct the error.

 

The Company identified an immaterial error in the financial statements related to the allocation of deferred revenue to earned revenue related to IRB studies (rolled up in “medical procedures” revenues). Initially, the Company amortized the incurred revenue over the portion of the IRB study related to the “treatment phase” of the patients. However, considering that the Company continued to incur costs associated with an option for the study participants to continue their treatment over a “crossover period” post conclusion of the treatment phase, the Company found it more accurate to recognize and amortize the revenue of the IRB study over the period to include both the treatment phase and the optional crossover period.

 

Going forward, the same methodology will be applied to future IRB studies. The error was previously evaluated and determined not to be material to the Company’s financial statements.

 

After giving effect to this correction during the three and six month ended June 30, 2026, there are no impacts to retained earnings nor shareholder’s equity (deficit) as relates to the three and nine months ended September 30, 2026, as the initial IRB that cause this amortization of revenue to come to our attention concluded prior to the end of September 30, 2026.

 

Therefore, the only impact is to revenue and the net income for the three and six months ended June 30, 2026. The only permanent impact to retained earnings at June 30, 2026, thereby impacting stockholders’ equity (deficit) as of June 30, 2026. In addition, the Company carried an additional $96,800 in deferred revenue on its balance sheet at June 30, 2026, to offset the aforementioned adjustments effectively.

 

 

 13 

 

 

ADIA MED, , INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

                
  

For the Three Months Ended

June 30, 2026

(as reported)

   Topside Adjustment  

For the Three Months Ended

June 30, 2026

(revised)

 
Revenue               
Sales of supplements  $–   $–   $– 
Medical procedures   329,820    (96,800)   233,020 
Sales of biologics   151,750    –    151,750 
Services   –    –    – 
Shipping and delivery   3,815    –    3,815 
Total Revenue   485,385    (96,800)   388,585 
                
Cost of Revenue               
Supplements   –    –    – 
Procedures   82,588    –    82,588 
Biologics   120,217    –    120,217 
Total Cost of Revenue   202,805    –    202,805 
                
Gross Profit   282,580    (96,800)   185,780 
                
Operating Expenses               
General and administrative   23,175    –    23,175 
Advertising and promotion   22,436    –    22,436 
Clinical trial fees   7,175    –    7,175 
Corporate filing fees   7,723    –    7,723 
Equipment leases   6,696    –    6,696 
Legal and professional fees   81,922    –    81,922 
Public relations   2,480    –    2,480 
Repairs and maintenance   1,152    –    1,152 
Rent   19,748    –    19,748 
Research and development   –    –    – 
Salaries and wages   55,129    –    55,129 
Utilities   1,672    –    1,672 
Depreciation and amortization   1,443    –    1,443 
Total Operating Expenses   230,751    –    230,751 
                
Income (Loss) from Operations   51,829    (96,800)   (44,971)
                
Other Income (Expense)               
Interest income   375    –    375 
Interest expense – related party   (11,786)   –    (11,786)
Total Other Income (Expense)   (11,411)   –    (11,411)
                
Net Income (Loss) Before provision for Income Taxes   40,418    (96,800)   (56,382)
                
Provision for Income Taxes   –    –    – 
                
NET INCOME (LOSS)  $40,418   $(96,800)  $(56,382)

 

 

 

 14 

 

 

                
  

For the Six Months Ended

June 30, 2026

(as reported)

   Topside Adjustment  

For the Six Months Ended

June 30, 2026

(revised)

 
Revenue               
Sales of supplements  $–   $–   $– 
Medical procedures   434,670    (96,800)   337,870 
Sales of biologics   221,525    –    221,525 
Services   –    –    – 
Shipping and delivery   5,465    –    5,465 
Total Revenue   661,660    (96,800)   564,860 
                
Cost of Revenue               
Supplements   –    –    – 
Procedures   153,550    –    153,550 
Biologics   157,953    –    157,953 
Total Cost of Revenue   311,503    –    311,503 
                
Gross Profit   350,157    (96,800)   253,357 
                
Operating Expenses               
General and administrative   56,952    –    56,952 
Advertising and promotion   59,443    –    59,443 
Clinical trial fees   12,025    –    12,025 
Corporate filing fees   11,728    –    11,728 
Equipment leases   13,392    –    13,392 
Legal and professional fees   160,731    –    160,731 
Public relations   4,920    –    4,920 
Repairs and maintenance   2,162    –    2,162 
Rent   35,931    –    35,931 
Research and development   –    –    – 
Salaries and wages   87,731    –    87,731 
Utilities   2,538    –    2,538 
Depreciation and amortization   2,695    –    2,695 
Total Operating Expenses   450,248    –    450,248 
                
Income (Loss) from Operations   (100,091)   (96,800)   (196,891)
                
Other Income (Expense)               
Interest income   750    –    750 
Interest expense – related party   (22,766)   –    (22,766)
Total Other Income (Expense)   (22,016)   –    (22,016)
                
Net Income (Loss) Before provision for Income Taxes   (122,107)   (96,800)   (218,907)
                
Provision for Income Taxes   –    –    – 
                
NET INCOME (LOSS)  $(122,107)  $(96,800)  $(218,907)

 

 

 

 15 

 

 

ADIA MED, INC.

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY (DEFICIT) (UNAUDITED)

                                 
   Special 2022 Series A Preferred   Series A Preferred   Series C Preferred   Shares to be issued 
   Shares   Amount ($)   Shares   Amount ($)   Shares   Amount ($)   Shares   Amount ($) 
Balance December 31, 2025   1    1    –    –    1,750,000    1,750    2,875,000    152,607 
                                         
Net loss   –    –    –    –    –    –    –    – 
Balance March 31, 2026   1    1    –    –    1,750,000    1,750    2,875,000    152,607 
                                         
Net loss   –    –    –    –    –    –    –    – 
Balance June 30, 2026   1    1    –    –    1,750,000    1,750    2,875,000    152,607 

(continued)

 

                             
   Class A Common Stock   Class B Common Stock   Additional Paid-In   Accumulated  

Total

Stockholders’

Equity

 
   Shares   Amount ($)   Shares   Amount ($)   Capital ($)   Deficit ($)   (Deficit) ($) 
Balance December 31, 2025   94,404,696    94,405    –    –    15,467,045    (15,973,482)   (257,674)
                                    
Net loss   –    –    –    –    –    (162,525)   (162,525)
Balance March 31, 2026   94,404,696    94,405    –    –    15,467,045    (16,136,007)   (420,199)
                                    
Net loss   –    –    –    –    –    (56,382)   (56,382)
Balance June 30, 2026   94,404,696    94,405    –    –    15,467,045    (16,192,389)   (476,581)

 

Principles of Consolidation

 

The condensed consolidated financial statements have been prepared in accordance with GAAP. The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries (Adia Labs, LLC and Adia Med of Winter Park, LLC). All intercompany balances and transactions have been eliminated.

 

Cash and Cash Equivalents

 

The Company accounts for cash and cash equivalents under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 305, “Cash and Cash Equivalents,” and considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.

 

 

 

 16 

 

 

Advertising and Promotion Costs

 

Advertising and promotion costs are expensed as incurred. These expenses were $16,400 and $23,794 for the three months ended September 30, 2026 and 2025, respectively, and $75,843, and $54,979 for the nine months ended September 30, 2026 and 2025, respectively.

 

Revenue Recognition

 

The Company records transactions in accordance with ASU 2014-09, “Revenue from Contracts with Customers” and all subsequent amendments to the ASU (collectively, “ASC 606”). In accordance with ASC 606, revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services.

 

Our operations currently generate revenues from the sale of our biologic products, the performance of medical procedures, sales of ancillary products, shipping and delivery, and other services. During the nine months ended September 30, 2026 and 2025, the Company had revenues of $1,019,245 and $521,958, respectively. Revenue was generated from the following sources:

                
   September 30, 2026   September 30, 2025 
Sales of supplements  $–    0.0%   $3,393    0.7% 
Medical procedures   576,770    56.6%    198,600    38.0% 
Sales of biologics   433,260    42.5%    313,010    60.0% 
Services   –    –    2,267    0.4% 
Shipping and delivery   9,215    0.9%    4,688    0.9% 
Total Revenue  $1,019,245    100.0%   $521,958    100.0% 

 

Costs of Revenues

 

Our policy is to recognize costs of revenue in the same manner in conjunction with revenue recognition. Cost of revenues include the costs directly attributable to revenue. Cost of revenue was the cost of our supplement products, the fees associated with the administration of medical procedures, and costs of our biologic products. For the nine months ended September 30, 2026 and 2025, cost of revenue was $544,907 and $278,497, respectively. Cost of revenue was as a result of the following:

                
   September 30, 2026   September 30, 2025 
Cost of supplements  $–    0.0%   $1,057    0.4% 
Cost for administration of medical procedures   160,674    29.5%    93,315    33.5% 
Cost of biologics   384,233    70.5%    184,125    66.1% 
Total Cost of Revenue  $544,907    100.0%   $278,497    100.0% 

 

 

 

 17 

 

 

Income Taxes and Valuation Allowance

 

The Company accounts for income taxes under ASC 740, “Income Taxes”. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. All of the Company’s deferred tax assets were offset by a full valuation allowance for September 30, 2026 and December 31, 2025.

 

Financial Instruments

 

ASC 820, “Fair Value Measurements and Disclosures,” defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

 

  Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
     
  Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
     
  Level 3 - Inputs that are both significant to the fair value measurement and unobservable.

 

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2026. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.

 

The Company does not have any assets or liabilities measured at fair value on a recurring basis.

 

 

 

 18 

 

 

Related Parties

 

The Company follows ASC 850-10, “Related Party Disclosures,” for the identification of related parties and disclosure of related party transactions. The CEO and Director of the Company has provided working capital to the Company on the line of credit facility he has extended to the Company.

 

Pursuant to ASC 850-10-20, related parties include: a) affiliates of the Company; b) principal owners of the Company; c) management of the Company; d) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and e) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

 

Material related party transactions are required to be disclosed in the consolidated financial statements, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: a) the nature of the relationship(s) involved; b) a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which statements of operation are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c) the dollar amounts of transactions for each of the periods for which statements of operations are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d) amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.

 

Commitments and Contingencies

 

The Company follows ASC 450-20, “Loss Contingencies,” to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.

 

Earnings (loss) per share

 

Basic income (loss) per share is computed by dividing net income (loss) attributable to common stockholders by the weighted average common shares outstanding for the period. Diluted income (loss) per share is computed giving effect to all potentially dilutive common shares. Potentially dilutive common shares may consist of incremental shares issuable upon the exercise of stock options and warrants and upon the conversion of notes. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. The number of potentially dilutive common shares (if the preferred shares were converted) for the three and nine months ended September 30, 2026 and 2025, are 67,000,000 and 77,500,000, respectively (this does not include the preferred shares logged as “shares to be issued”),

 

 

 

 19 

 

 

Inventory

 

Inventories are carried at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of applicable variable selling expenses. Management periodically evaluates if a reserve is necessary, and management determined that a reserve was not necessary at September 30, 2026 and December 31, 2025.

 

Investments

 

In accordance with ASC 321, “Investments – Equity Securities,” our investment in Cement Factory, LLC is stated at cost, as our investment in this entity constitutes less than 20% in Cement Factory, LLC and does not provide the Company control over this entity. The original agreement entered into was rescinded, and replaced with an agreement to acquire an 18% membership interest in Cement Factory, LLC, allowing the Company to receive an 18% dividend income from Cement Factory paid annually at the end of each calendar year based on profitability. (See Note 9.)

 

Leases

 

In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, “Leases” Topic 842, which amends the guidance in former ASC Topic 840, Leases (“ASC 840”). The new standard increases transparency and comparability most significantly by requiring the recognition by lessees of right-of-use (“ROU”) assets and lease liabilities on the balance sheet for all leases longer than 12 months. Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. For lessees, leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement, over the expected term on a straight-line basis. We determine if an arrangement is a lease at inception. The Company recognizes ROU assets and lease liabilities for leases with terms greater than 12 months or leases that contain a purchase option that is reasonably certain to be exercised. Leases are classified as either finance or operating leases. This classification dictates whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. Operating leases are included in operating lease ROU assets and operating lease liabilities on our condensed consolidated balance sheets. Finance leases are included in finance lease assets, current finance lease liabilities, and long-term finance lease liabilities on our condensed consolidated balance sheets.

 

The Company’s ROU assets and lease liabilities are recognized on the lease commencement date in an amount that represents the present value of future lease payments over the lease term. The Company utilizes its collateralized incremental borrowing rate commensurate to the lease term as the discount rate for its leases unless the Company can specifically determine the lessor’s implicit rate. Certain lease contracts contain non-lease components such as maintenance and utilities. The Company has made a policy election to not separate the lease and non-lease components, and thus recognize a single lease component for all of its right-of-use assets and liabilities.

 

In evaluating contracts to determine if they qualify as a lease, the Company considers factors such as if it has obtained substantially all of the rights to the underlying asset through exclusivity, if the Company can direct the use of the asset by making decisions about how and for what purpose the asset will be used and if the lessor has substantive substitution rights. Furthermore, the Company assesses whether it is reasonably certain to exercise options to extend or terminate a lease considering all relevant factors that create economic incentive to exercise such options, including asset, contract, market, and entity-based factors. These evaluations may require significant judgment.

 

 

 

 20 

 

 

Loss Contingencies

 

From time to time the Company may be subject to various legal proceedings and claims that arise in the ordinary course of business. On at least a quarterly basis, consistent with ASC 450-20-50-1C, if the Company determines that there is a reasonable possibility that a material loss may have been incurred, or is reasonably estimable, regardless of whether the Company accrued for such a loss (or any portion of that loss), the Company will confer with its legal counsel, consistent with ASC 450. If the material loss is determinable or reasonably estimable, the Company will record it in its accounts and as a liability on the condensed consolidated balance sheet.

 

Fixed Assets

 

The Company follows ASC 360, “Property, Plant, and Equipment,” for its fixed assets. Equipment is stated at cost less accumulated depreciation. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets (3 to 7 years for equipment). Depreciation expense for the three months ended September 30, 2026 and 2025, was $1,647 and $1,262, respectively, and $4,341 and $3,178 for the nine months ended September 30, 2026 and 2025, respectively.

 

Long-lived Assets

 

Long-lived assets such as fixed assets and identifiable intangibles are reviewed for impairment whenever facts and circumstances indicate that the carrying value may not be recoverable. When required impairment losses on assets to be held and used are recognized based on the fair value of the asset. The fair value is determined based on estimates of future cash flows, market value of similar assets, if available, or independent appraisals, if required. If the carrying amount of the long-lived asset is not recoverable from its undiscounted cash flows, an impairment loss is recognized for the difference between the carrying amount and fair value of the asset. When fair values are not available, the Company estimates fair value using the expected future cash flows discounted at a rate commensurate with the risk associated with the recovery of the assets. We did not recognize any impairment losses for any periods presented.

 

Segment Reporting

 

Operating segments are components of an enterprise about which separate financial information is available and is evaluated regularly by management, namely the Chief Operating Decision Maker (“CODM”) of an organization, in order to determine operating and resource allocation decisions. By this definition, the Company has identified its Chief Executive Officer as the CODM. The CODM has identified Adia Labs and Adia Med as the Company’s operating segments.

 

Stock-Based Compensation

 

FASB ASC 718 “Compensation – Stock Compensation,” prescribes accounting and reporting standards for all stock-based payments award to employees, including employee stock options, restricted stock, employee stock purchase plans and stock appreciation rights, may be classified as either equity or liabilities. The Company determines if a present obligation to settle the share-based payment transaction in cash or other assets exists. A present obligation to settle in cash or other assets exists if: (a) the option to settle by issuing equity instruments lacks commercial substance or (b) the present obligation is implied because of an entity’s past practices or stated policies. If a present obligation exists, the transaction should be recognized as a liability; otherwise, the transaction should be recognized as equity.

 

 

 

 21 

 

 

The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of FASB ASC 505-50 “Equity – Based Payments to Non-Employees.” Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date. For the three months ended September 30, 2026 and 2025, the Company did not have any share-based compensation.

 

Recently Issued Accounting Pronouncements

 

We have reviewed the FASB issued ASU accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted accounting principles and does not believe that any new or modified principles will have a material impact on the corporation’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration. For the year ended December 31, 2025, we adopted the ASU 2023-09, “Income Taxes (Topic 740) Improvement to Income Tax Disclosure”, to appropriately reconcile to specific tax rate provisions. As a result, certain prior year amounts have been reclassified for consistency with current year presentation.

 

NOTE 4 – ACCOUNTS RECEIVABLE AND ALLOWANCE FOR CREDIT LOSSES

 

Accounts receivable are stated at amortized cost and consist primarily of trade receivables from customers arising from the sale of goods/services in the ordinary course of business. The Company estimates expected credit losses on accounts receivable using relevant available information from internal and external sources, including historical credit loss experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amounts.

 

The Company's historical credit loss experience on trade receivables, adjusted for current conditions and reasonable and supportable forecasts of future economic conditions, results in an expectation that nonpayment of the amortized cost basis is zero. This assessment considers factors such as the credit quality of customers, short collection periods, low historical default rates, and no material adverse changes expected in relevant economic conditions or customer circumstances.

 

Accordingly, no allowance for credit losses has been recorded as of September 30, 2026 and December 31, 2025, and no credit loss expense related to accounts receivable was recognized during the three and nine months ended September 30, 2026 and the year ended December 31, 2025.

 

NOTE 5 - INVENTORY

 

Inventory consists of the following:

        
  

September 30,

2026

   December 31, 
2025
 
Biologic products  $78,500   $25,025 
Pre-paid inventory   270,000    – 
Total Inventory  $348,500   $25,025 

 

 

 

 22 

 

 

NOTE 6 – FIXED ASSETS, NET

 

Fixed assets, net, consists of the following:

        
  

September 30,

2026

   December 31,
2025
 
Furniture and fixtures  $5,332   $5,332 
Machinery and equipment   45,134    29,698 
Property and equipment, gross   50,466    35,030 
Less: Accumulated depreciation   (8,676)   (4,335)
Total Fixed Assets, Net  $41,790   $30,695 

 

NOTE 7 – NOTE RECEIVABLE

 

On September 30, 2026, the Company, its subsidiary Adia Labs LLC, and Live Oak Health LLC (d/b/a QCM Biologics), entered into a Membership Interest Purchase Agreement (see Note 13). Under the Purchase Agreement, QCM Biologics agreed to purchase a membership interest in Adia Labs. The purchase price of $1,500,000 ($1,000,000 in immediate cash, and $500,000 via by delivery of a promissory note. The note in the original principal amount of $500,000, bears interest at 7% per annum on unpaid principal, calculated on a 30/360 basis, and provides for interest-only monthly payments for a period of 48 months, beginning October 30, 2026. The entire unpaid principal and accrued and unpaid interest, is due on the maturity date of September 30, 2030. The Note may be prepaid in whole or in part at any time without penalty. After notice and a 10-day cure period, the default rate is 12% per annum. A late charge of 5% applies to any payment more than 10 days late. The note is secured by a first-priority pledge of the membership interest until paid in full. Default under the note or the pledge is considered a default on of the Purchase Agreement. After the applicable cure period, the Company may accelerate the Note, enforce the pledge, and exercise other lawful remedies. At September 30, 2026 and December 31, 2025, the principal amount due to the Company is $500,000 and $0, respectively; and the total accrued interest due to the Company at September 30, 2026 and December 31, 2025 is $0.

 

NOTE 8 – ACQUISITION OF NEW BUSINESS

 

On July 11, 2024, the Company acquired a 100% membership interest in Biolete, LLC, a company involved in the development of a protein coffee with mushroom extracts. This acquisition was treated as an asset acquisition valued at $72,000, in which the Company received $70,000 in inventory, and a trademark on the product valued at $2,000. Subsequently, the Company invested additional monies to acquire additional trademarks. Consideration provided for this acquisition was the issuance of 1,750,000 shares of the Company’s Series C Preferred Stock. Going forward from the acquisition date the revenue and expenses associated with the Biolete brand have been consolidated with the Company’s reported financials.

 

On September 30, 2025, the Company sold the inventory on hand and the associated trademarks of the Biolete brand to Cement Factory, in which the Company continues to hold an 18% membership interest. The Company transferred the inventory at cost totaling $66,192, all of the trademarks on the Biolete brands net of amortization totaling $5,463, and the cost of the investment into the Biolete website totaling $706, as a result the Company has recorded a receivable in the amount of $72,361 on the transfer date. During the nine months ended September 30, 2026 and the year ended December 31, 2025, Cement Factory made payments totaling $376 and $254, respectively, toward this receivable, resulting in an amount due of $71,731 at September 30, 2026 and December 31, 2025, respectively.

 

 

 

 23 

 

 

NOTE 9 – INVESTMENT IN NON-CONSOLIDATED BUSINESS ENTITY

 

On July 29, 2024, the Company acquired a 7% membership interest in Cement Factory Nutrition, a health and wellness company. Consideration provided for this acquisition was the issuance of 1,875,000 shares of the Company’s Series C Preferred Stock. On September 24, 2024, the agreement for the acquisition of the membership interest in Cement Factory Nutrition was rescinded and replaced with the acquisition of 18% membership interest in Cement Factory, LLC. Going forward, the Company will receive 18% dividend income from Cement Factory paid annually at the end of each calendar year based on profitability. Our investment in Cement Factory, LLC is stated at cost, as our investment in this entity constitutes less than 20% in Cement Factory, LLC and does not provide the Company control over this entity. To date, Cement Factory has not generated a profit; as a result, for the three and nine months ended September 30, 2026 and 2025, the Company did not receive any dividend income.

 

NOTE 10 – RELATED PARTY TRANSACTIONS

 

On June 30, 2024, the Company entered into an agreement with the Chief Executive Officer of the Company for an unsecured $500,000 line of credit facility. Total credit was increased to $750,000 with the addition of another $250,000 line of credit facility on June 12, 2025, and an additional $250,000 on May 12, 2026, bearing the same terms as the original line of credit. The total line of credit available from the Chief Executive Officer is currently $1,000,000. The line of credit bears interest of 6% per annum calculated on a daily basis, and there is no stated maturity date. The entire unpaid principal balance plus any accrued but unpaid interest shall be due and payable twelve months from the date of receipt of demand of payment by the lender. During the year ended December 31, 2025, the Company received advances of $231,471 and during the nine months ended September 30, 2026, the Company received advances of $462,812 and repaid a total of $127,500. At September 30, 2026 and December 31, 2025, the total outstanding principal balance on this line of credit facility was $935,312 and $600,000, respectively. For the three months ended September 30, 2026 and 2025, interest expense was $13,990 and $9,074, respectively, and for the nine months ended September 30, 2026 and 2025, interest expense was $36,756 and $22,160, respectively, and total accrued interest at September 30, 2026 and December 31, 2025, was $74,672 and $37,915, respectively.

 

The above amounts and terms of the transactions are not necessarily typical of agreements entered into by third parties.

 

NOTE 11 – LOANS TO CLINICS

 

On July 15, 2025, the Company provided a start-up loan to Aspire Regenerative Therapy in the amount of $25,000. The terms of the loan are for the principal to be repaid in 5 years at 6% interest per annum. The Company has agreed to receive interest only payments for the first year. At September 30, 2026 and December 31, 2025, the total outstanding principal balance on this loan was $25,000. For the three months ended September 30, 2026 and 2025, interest income was $125 and $0, respectively, and $875 and $0 for the nine months ended September 30, 2026 and 2025, respectively.

 

On April 6, 2026, the Company paid the IRB fees on behalf of Greater Atlanta Integrative Pediatrics (“GAIP”) required to conduct a clinical study for autism. The payment of the fees are treated as a loan to GAIP in the amount of $5,300. GAIP will pay the Company an additional $100 per vial of biologics order from the Company until the balance of the loan is repaid. For the three and nine months ended September 30, 2026 and 2025, there were no repayments towards this loan, and at September 30, 2026, the balance of the loan is $5,300.

 

 

 

 24 

 

 

NOTE 12 - LEASES

 

The Company has an operating lease for office space and a finance lease for equipment. Leasing arrangements require fixed payments and also include an amount that is probable and will be owed under residual value guarantees, if applicable. Lease payments also include payments related to purchase or termination options when the lessee is reasonably certain to exercise the option or is reasonably certain not to exercise the option, respectively. The Company’s lease agreements do not contain any material restrictive covenants. The leases have remaining terms of 3 to 5 years. The Company executed a finance lease during the year ended December 31, 2024, the lease period commenced January 1, 2025.

 

The Company’s right-of-use assets and lease liabilities and other disclosures at September 30, 2026 and at December 31, 2025, are as follows:

        
   Operating Lease   Finance Lease 
Right-of-use assets obtained in exchange for new lease liabilities  $160,447   $130,294 
Weighted-average remaining lease term   1.08 years    2.25 years 
Weighted average discount rate   7.9%    9.9% 

                 
   Operating Lease   Finance Lease 
  

September 30,

2026

  

Dec. 31,

2025

  

September 30,

2026

  

Dec. 31,

2025

 
Right-of-use assets  $160,447   $160,447   $130,294   $130,294 
Less: amortization   94,819    52,604    39,870    22,123 
Lease assets, net  $65,628   $107,843   $90,424   $108,171 
                     
Lease liabilities                    
Lease liabilities, current  $65,219   $63,950   $26,784   $26,784 
Lease liabilities, long-term   2,448    45,918    44,890    61,387 
Total lease obligation  $67,667   $109,868   $71,674   $88,171 

 

Future payments of lease liabilities at September 30, 2026 are as follows:

        
Year Ending December 31,  Operating Lease   Finance Lease 
2026  $16,185   $6,696 
2027   54,482    26,784 
2028   –    26,784 
2029   –    26,784 
Thereafter   –    – 
    70,667    87,048 
Less interest   (3,000)   (15,374)
Total  $67,667   $71,674 

 

 

 

 25 

 

 

NOTE 13 – STOCKHOLDERS’ EQUITY

 

Other Equity Transactions

 

On September 30, 2026, Adia Med, Inc., the Company’s subsidiary Adia Labs LLC, and Live Oak Health LLC, a Florida limited liability company doing business as QCM Biologics entered into a Membership Interest Purchase Agreement. David Konn is the sole member and manager of QCM Biologics, and is not, to the Company’s knowledge, an affiliate of the Company.

 

Under the Purchase Agreement, the Company agreed to sell, and QCM Biologics agreed to purchase, 30 units of membership interest in the Adia Labs, representing 30% of the 100 units issued and outstanding, at $50,000 per unit, or $1,500,000 in the aggregate. The purchase price of $1,500,000 was payable via $1,000,000 in cash immediately, and $500,000 via a promissory note (see Note 7). The purchased units are to be transferred free and clear of liens other than a first-priority pledge of the purchased units securing the promissory note.

 

The Company also granted Buyer an option to purchase up to 10 additional units at $50,000 per unit, or $500,000 if exercised in full. The option may be exercised in whole units, in one or more exercises, at any time after closing until 5pm EST on September 30, 2028 (at which point the option expires). The option is personal to Buyer and may not be assigned without the Company’s prior written consent, except to an affiliate wholly owned by Mr. Konn. The option adjusts only for a unit split or recapitalization that does not change relative ownership. Except for the purchased units and the option units, the Company is not obligated to sell Buyer any other interest in the Adia Labs. If the option is exercised in full and no other units are issued or transferred, the Company would own 60 units (60% in Adia Labs). Economic ownership follows units and voting power does not. If the option I exercised, and from the first day Buyer purchases the additional units, the Company and buyer each have 50% of the voting power on all member matters, even though the Company owns 70% of the units and Buyer owns 30%. Equal voting continues if Buyer later purchases any or all of the Option units. Equal voting applies to member votes, consents, and approvals under the operating agreement and Florida law, including amendment of the operating agreement, issuance or repurchase of units, admission of new members, sale, merger, or dissolution, the annual budget and material debt, appointment or removal of managers, related-party transactions, and distributions other than tax distributions required by the operating agreement. Equal voting does not change distributions, profit and loss allocations, or sale proceeds, which follow units, except for tax distributions required by the operating agreement.

 

Common Stock

 

The Company has 900,000,000 authorized common shares with a par value of $0.001 per share. Each common share entitles the holder to one vote, in person or proxy, on any matter on which action of the stockholders of the corporation is sought.

 

The Company has two common stock designations; Class A Common Stock with 800,000,000 shares authorized, and Class B Common Stock with 100,000,000 shares authorized.

 

Class A Common Stock: Each share of Class A Common Stock shall have, for all purposes, one (1) vote per share. Subject to the preferences applicable to Preferred Stock outstanding at any time, the holders of the shares of Class A Common Stock shall be entitled to receive such dividends and other distributions in cash, property or shares of stock of the Corporation as may be declared thereon by the Board of Directors from time to time out of assets or funds of the Corporation legally available therefrom. The holders of Class A Common Stock issued and outstanding have and possess the right to receive notice of shareholders’ meetings and to vote upon the election of directors or upon any other matter as to which approval of the outstanding shares of Class A Common Stock or approval of the common shareholders is required or requested.

 

 

 

 26 

 

 

Class B Common Stock: The shares of Class B Common Stock may be issued from time to time in one or more series. The Board of Directors is authorized, by resolution adopted and filed in accordance with law, to provide for the issue of each series of shares of Class B Common Stock; provided, however, that any issuance of shares of Class B Common Stock shall be made only in connection with a special acquisition transaction, as determined by the Board of Directors. Each series of shares of Class B Common Stock: (a) may have such voting powers, full or limited or may be without voting powers; (b) may be subject to redemption at such time or times and at such prices as determined by the Board of Directors; (c) may be entitled to receive dividends (which may be cumulative or non-cumulative) at such rate or rates, on such conditions and at such times, and payable in preference to, or in relation to, the dividends payable on any other class or classes or series of stock; (d) may have such rights upon the dissolution of, or upon any distribution of assets of, the Corporation; (e) may be made convertible into, or exchangeable for, shares of any other class or classes or of any other series of the same or any other class or classes of stock of the Corporation or such other corporation or other entity at such price or prices or at such rates of exchange and with such adjustments; (f) may be entitled to the benefit of a sinking fund to be applied to the purchase or redemption of shares of such series in such amount or amounts; (g) may be entitled to the benefit of conditions and restrictions upon the creation of indebtedness of the Corporation or any subsidiary, upon the issue of any additional shares (including additional shares of such series or of any other series) and upon the payment of dividends or the making of other distributions on, and the purchase, redemption or other acquisition by the Corporation or any subsidiary of, any outstanding shares of the Corporation; and (h) may have such other relative, participating, optional or other special rights, qualifications, limitations or restrictions thereof, in each case as shall be stated in said resolution or resolutions providing for the issue of such shares of Class B Common Stock. Shares of Class B Common Stock of any series that have been redeemed or repurchased by the Corporation (whether through the operation of a sinking fund or otherwise) or that, if convertible or exchangeable, have been converted or exchanged in accordance with their terms shall be retired and have the status of authorized and unissued shares of Class B Common Stock of the same series and may be reissued as a part of the series of which they were originally a part or may, upon the filing of an appropriate certificate with the Secretary of State of the State of Nevada be reissued as part of a new series of shares of Class B Common Stock to be created by resolution or resolutions of the Board of Directors or as part of any other series of shares of Class B Common Stock, all subject to the conditions or restrictions on issuance set forth in the resolution or resolutions adopted by the Board of Directors providing for the issue of any series of shares of Class B Common Stock.

 

On July 9, 2024, the Company received an investment on its Reg A registration statement in the amount of $40,000 in investments, offset by $15,000 in offering costs, resulting in subsequent issuance of 8,000,000 shares of the Company’s Class A Common Stock.

 

On May 5, 2025, the Company retired 15,495,165 shares of its Common Stock. Initially, on May 31, 2024, the Company filed a complaint for declaratory relief, seeking an order declaring as void a total of 15,495,165 shares of the Company’s issued and outstanding shares of Common Stock, held by Lotus Fund (“Lotus”) (10,495,165 shares), and Jason S. Coombs (“Coombs”) (5,000,000 shares), as well as the certain issued and outstanding shares of Series A Preferred Shares. Lotus, Coombs and Singhal (collectively the “Claimants”) were issued these shares but the Company deems that they were not properly acquired through any consideration. The lawsuit (Case Number: 2024CA001088, Case Style: ADIA NUTRITION INC -VS- ADIA NUTRITION INC) was filed pursuant to the laws of the State of Florida, and the venue lies in Seminole County. This matter was settled in favor of the Company on May 5, 2025.

 

On June 6, 2025, the Company received an investment on its Reg A registration statement in the amount of $38,500 in investments, offset by $15,000 in offering costs, resulting in shares to be issued of 7,700,000 shares of the Company’s Class A Common Stock, which were then issued on July 22, 2025.

 

On June 11, 2025, the Company received an investment on its Reg A registration statement in the amount of $31,500 in investments, offset by $15,000 in offering costs, resulting in shares to be issued of 6,300,000 shares of the Company’s Class A Common Stock, which were then issued on July 22, 2025.

 

On September 16, 2026, the Company filed a Verified Complaint for Declaratory Judgement (the “Complaint”) in the Circuit Court of the Eighteenth Judicial Circuit in and for Seminole County, Florida, styled In Re Stock of ADIA MED, INC. v. Tydus Richards, Case No. 2026CA002155 (the “Action”). The Action is a declaratory-judgment proceeding seeking to quiet title in 29,059,792 shares of the Company’s non-preferred common stock (the “Subject Shares”). The Complaint alleges that the Subject Shares represent 30.78% of the Company’s issued and outstanding shares. The caption names Tydus Richards as the defendant. The Complaint alleges, among other things, that in January 2024 a change of control of the Company occurred when all Special 2022 Series A Preferred stock, carrying 60% of the voting rights, was acquired by Legends Investment Properties, LLC, a Florida limited liability company; that, in connection with that acquisition, the Company determined there was no basis in its records, and no record at its transfer agent of original issuance, supporting the Claimants’ positions as reflected on the shareholder list; that the Claimants’ asserted interests rest solely on the stock transfer ledger; and that, upon information and belief, the Claimants never paid for the Subject Shares and the Subject Shares were not validly issued. The Complaint seeks a judgment declaring that title to the improperly issued Subject Shares is quieted in the Company, and an order restraining each Claimant from instituting an action against the Company for recovery of the Subject Shares or any part of them, together with such other relief as the court deems just and proper. The Company is the plaintiff in the Action. No responsive pleading has been filed, and no hearing has been set, as of the date of this report. The Company intends to pursue the Action. The outcome is uncertain. The Claimants may appear, contest jurisdiction or venue, assert that the Subject Shares were validly issued or transferred, or bring related claims. An adverse result would leave the Subject Shares outstanding in the names of the Claimants. A judgment quieting title in the Company would, if entered and given effect by the transfer agent, reduce the number of shares of common stock deemed issued and outstanding by up to 29,059,792 shares. The Company has not cancelled the Subject Shares, and it will not treat the Subject Shares as retired unless and until a court of competent jurisdiction so orders and the transfer agent records the cancellation. The Company cannot predict the timing or outcome of the Action, or the amount of legal expense it will incur.

 

 

 

 27 

 

 

At September 30, 2026 and December 31, 2025, there were 94,404,696 Class A Common Shares issued and outstanding.

 

At September 30, 2026 and December 31, 2025, there were no Class B Common Shares issued and outstanding.

 

Preferred Stock

 

There are 100,000,000 shares of preferred stock authorized, par value $.001 per share (the “Preferred Stock”), issuable in one or more series; (a) the Company designated one (1) share of Preferred Stock as “Special 2022 Series A Preferred Stock” possessing super-voting rights; (b) the Company designated 10,000,000 shares of Series A Preferred Stock; and (c) the Company designated 89,999,999 shares of Series C Preferred Stock.

 

Special 2022 Series A Preferred Stock. The designation of this class of preferred stock shall be “Special 2022 Series A Preferred Stock,” par value $.001 per share (the “Special 2022 Series A Preferred Stock”). The number of authorized shares of Special 2022 Series A Preferred Stock is one (1). (A) Voting Rights. Except as otherwise required by law, the holder of the share of Special 2022 Series A Preferred Stock shall have the following rights: (1) Number of Votes; Voting with Common Stock. Except as provided by Nevada statutes or elsewhere herein, the holder of the Special 2022 Series A Preferred Stock shall vote together with the holders of Preferred Stock (including on an as converted basis), and Common Stock, of the Corporation as a single class. The holder of the share of Special 2022 Series A Preferred Stock is entitled to 60% of all votes (including, but not limited to, Common Stock, and Preferred Stock (including on an as converted basis) entitled to vote at each meeting of shareholders of the Corporation (and written actions of shareholders in lieu of meetings) with respect to any and all matters presented to the shareholders of the Corporation for their action or consideration. The share of Special 2022 Series A Preferred Stock shall not be divided into fractional shares. (2) Adverse Effects. The Corporation shall not amend, alter, or repeal the preferences, rights, powers or other terms of the Special 2022 Series A Preferred Stock so as to affect adversely the Special 2022 Series A Preferred Stock, or the holder thereof, without the written consent or affirmative vote of the holder of the Special 2022 Series A Preferred Stock given in writing or by vote at a meeting, consenting or voting (as the case may be) separately as a class. (B) Conversion. The share of the Special 2022 Series A Preferred Stock shall convert into common shares at a conversion rate of 1 preferred to 60,000,000 common shares. The holder of the Special 2022 Series A Preferred stock can affect the conversion at any time. The conversion into common is a right and is not required. (C) Dividends; Liquidation. The shares of Special 2022 Series A Preferred Stock shall not be entitled to any dividends in respect thereof and shall not participate in any proceeds available to the Corporation’s shareholders upon the liquidation, dissolution or winding up of the Corporation. (D) No Impairment. The Corporation shall not intentionally take any action which would impair the rights and privileges of the Special 2022 Series A Preferred Stock set forth herein or the rights of the holder thereof. The Corporation will not, by amendment of its articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed hereunder by the Corporation, but will, at all times, in good faith assist in the carrying out of all the provisions herein and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the holder of the Special 2022 Series A Preferred Stock against impairment.

 

Series A Preferred Stock. The designation of this class of preferred stock shall be “Series A Preferred Stock,” par value $.001 per share (the “Series A Preferred Stock”). The number of authorized shares of Series A Preferred Stock is ten million (10,000,000). Each share of Series A Preferred Stock shall entitle the holder to five (5) votes on any matter submitted to the shareholders of the Corporation for their vote, waiver, release or other action, to be considered in connection with the establishment of a quorum, except as may otherwise be expressly required by law or by the applicable stock exchange rules. The holders of Series A Preferred Stock shall vote together with the shares of Common Stock as one class. (c) Liquidation Rights. Upon the dissolution, liquidation or winding up of the Corporation, whether voluntary or involuntary, the holders of the then-outstanding shares of Series A Preferred Stock shall be entitled to receive out of the assets of the Corporation the sum of $.001 per share (the “Liquidation Rate”) before any payment or distribution shall be made on any other class of capital stock of the Corporation ranking junior to the Series A Preferred Stock.

 

 

 

 28 

 

 

Series C Preferred Stock. The designation of this class of preferred stock shall be “Series C Preferred Stock,” par value $.001 per share (the “Series C Preferred Stock”). The number of authorized shares of Series C Preferred Stock is eighty-nine million, nine hundred ninety-nine thousand, nine hundred and ninety nine (89,999,999). Each share of Series C Preferred Stock shall entitle the holder to one (1) vote on any matter submitted to the shareholders of the Corporation for their vote, waiver, release or other action, to be considered in connection with the establishment of a quorum, except as may otherwise be expressly required by law or by the applicable stock exchange rules. The holders of Series C Preferred Stock shall vote together with the shares of Common Stock as one class.

 

Liquidation Rights - Upon the dissolution, liquidation or winding up of the Corporation, whether voluntary or involuntary, the holders of the then-outstanding shares of Series C Preferred Stock shall be treated pari passu with the Company’s common stock, except that the payment on each share of the Company’s common stock multiplied by the Conversion Rate. Conversion Rate – Each share of Series C Preferred Stock shall be convertible into four (4) shares of the Company’s common stock.

 

On July 11, 2024, the Company acquired a 100% membership interest in Biolete, LLC; consideration provided for this acquisition was the issuance of 1,750,000 shares of the Company’s Series C Preferred Stock.

 

On July 29, 2024, the Company acquired a 7% membership interest in Cement Factory Nutrition; consideration provided for this acquisition was the issuance of 1,875,000 shares of the Company’s Series C Preferred Stock. On September 24, 2024, the acquisition of the 7% interest in Cement Factory Nutrition was rescinded and these shares were returned and a new agreement was made to acquire and 18% membership interest in Cement Factory, LLC; consideration provided for this acquisition was the reservation of 1,875,000 shares of the Company’s Series C Preferred Stock. The Company issued the 1,875,000 shares of its Series C Preferred Stock to Cement Factory on July 27, 2026.

 

On August 19, 2024, the Company appointed Monica Sher, MD as a Director of Company. The Company issued 250,000 shares of its Series C Preferred Stock to the Director on July 27, 2026.

 

On September 10, 2024, the Company appointed Richard Edwards, DO as a Director of Company. The Company issued 250,000 shares of its Series C Preferred Stock to the Director on July 27, 2026.

 

On September 23, 2024, the Company appointed Kalpesh Barot, MD as a Director of Company. The Company will issue 250,000 shares of its Series C Preferred Stock at a future date.

 

On May 5, 2025, the Company retired and declared void 10,000,000 shares of the Company Series A Preferred Shares. Initially, on May 31, 2024, the Company filed a complaint for declaratory relief, seeking an order declaring as void certain shares of the Company’s issued and outstanding shares of Common Stock. In addition, the lawsuit sought an order declaring as void a total of 10,000,000 shares of the Company’s issued and outstanding shares of Series A Preferred Shares, held by Shelly Singhal (“Singhal”). The lawsuit (Case Number: 2024CA001088, Case Style: ADIA NUTRITION INC -VS- ADIA NUTRITION INC) was filed pursuant to the laws of the State of Florida, and the venue lies in Seminole County. This matter was settled in favor of the Company on May 5, 2025.

 

On October 13, 2025, the Company appointed Dr. Evan Thomas, MD, PhD. as an Independent Medical Director for the Company’s medical division, Adia Med. The Company issued 250,000 shares of its Series C Preferred Stock to the Director on July 27, 2026.

 

 

 

 29 

 

 

At the year ended December 31, 2025, per their employment agreements (fully ratified in 2026), two officers of the Company were entitled to the option to purchase a total of 15,000,000 shares of the Company’s Series C Preferred Stock, however, the Company is obligated to issue these shares at some point in the future, regardless if the options are exercised by the Company or not.

 

At September 30, 2026 and December 31, 2025, there is one (1) share of Special 2022 Series A Preferred issued and outstanding.

 

At September 30, 2026 and December 31, 2025, there are zero shares of Series A Preferred issued and outstanding.

 

At September 30, 2026 and December 31, 2025, there are 4,375,000 and 1,750,000 shares of Series C Preferred issued and outstanding, respectively.

 

NOTE 14 – SEGMENT REPORTING

 

During the year ended December 31, 2025, the Company had three operating segments: (1) Biolete, (2) Adia Med, and (3) Adia Labs. On September 30, 2025, the Company sold its rights to the Biolete trademarks and all associated assets to Cement Factory, and as a result for the nine months ended September 30, 2026, the Company had two operating segments: (1) Adia Med, and (2) Adia Labs.

        
  

September 30,

2026

   December 31,
2025
 
Adia Med assets  $304,751   $261,208 
Adia Labs assets   1,435,348    25,025 
Unallocated corporate assets   712,888    308,593 
Total Assets  $2,452,987   $594,826 

 

The CODM reviews performance based on gross profit (sales less cost of products or services sold), operating profit, and net income (loss). Profitability is important to the Company’s ability to grow and expand operations. The Company does not have any operations or sources of revenue outside of the United States. Corporate overhead is not allocated to each segment unless the cost is specifically incurred to support the single segment. This provides the CODM with segment specific costs and profits.

 

 

 

 30 

 

 

The Company chooses to disclose the following in its segment reporting requirements for the nine months ended September 30, 2026:

                    

For the nine months ended

September 30, 2026

  Unallocated                 
   Corporate       ADIA   ADIA     
   Overhead   Biolete   Med   Labs   Totals 
Segment Revenue                         
Medical procedures  $–   $–   $576,770   $–   $576,770 
Sales of biologics, net of discounts and refunds   –    –    –    433,260    433,260 
Shipping and delivery   –    –    –    9,215    9,215 
Total Segment Revenue   –    –    576,770    442,475    1,019,245 
                          
Cost of Revenue                         
Cost of goods sold   –    –    160,674    384,233    544,907 
                          
Gross Profit   –    –    416,096    58,242    474,338 
                          
Operating Expenses                         
General and administrative   353,287    –    241,517    39,732    634,536 
Advertising and promotion   1,126    –    74,717    –    75,843 
Segment Operating Expenses   354,413    –    316,234    39,732    710,379 
                          
Segment Profit (Loss)  $(354,413)  $–   $99,862   $18,510   $(236,041)

 

 

 

 31 

 

 

The Company chooses to disclose the following in its segment reporting requirements for the nine months ended September 30, 2025:

                     

For the nine months ended

September 30, 2025

  Unallocated                 
   Corporate       ADIA   ADIA     
   Overhead   Biolete   Med   Labs   Totals 
Segment Revenue                         
Medical procedures  $–   $–   $198,600   $–   $198,600 
Sales of biologics, net of discounts and refunds   –    –    –    313,010    313,010 
Sales of supplements   –    3,393    –    –    3,393 
Services   2,267    –    –    –    2,267 
Shipping and delivery   –    –    –    4,688    4,688 
Total Segment Revenue   2,267    3,393    198,600    317,698    521,958 
                          
Cost of Revenue                         
Cost of goods sold   –    1,057    93,315    184,125    278,497 
                          
Gross Profit   2,267    2,336    105,285    133,573    243,461 
                          
Operating Expenses                         
General and administrative   182,085    2,226    147,902    4,198    336,411 
Advertising and promotion   25,349    67    24,497    5,066    54,979 
Segment Operating Expenses   207,434    2,293    172,399    9,264    391,390 
                          
Segment Profit (Loss)  $(205,167)  $42   $(67,114)  $124,309   $(147,929)

 

NOTE 15 – COMMITMENTS AND CONTINGENCIES

 

On May 5, 2025, the Company retired 15,495,165 shares of its Common Stock and declared void 10,000,000 shares of the Company Series A Preferred Shares. Initially, on May 31, 2024, the Company filed a complaint for declaratory relief, seeking an order declaring as void a total of 15,495,165 shares of the Company’s issued and outstanding shares of Common Stock, held by Lotus Fund (“Lotus”) (10,495,165 shares), and Jason S. Coombs (“Coombs”) (5,000,000 shares). In addition, the lawsuit seeks an order declaring as void a total of 10,000,000 shares of the Company’s issued and outstanding shares of Series A Preferred Shares, held by Shelly Singhal (“Singhal”). Lotus, Coombs and Singhal (collectively the “Claimants”) were issued these shares but the Company deems that they were not properly acquired through any consideration. The lawsuit (Case Number: 2024CA001088, Case Style: ADIA NUTRITION INC -VS- ADIA NUTRITION INC) was filed pursuant to the laws of the State of Florida, and the venue lies in Seminole County. This matter was settled in favor of the Company on May 5, 2025.

 

On September 16, 2026, the Company filed a Verified Complaint for Declaratory Judgement (the “Complaint”) in the Circuit Court of the Eighteenth Judicial Circuit in and for Seminole County, Florida, styled In Re Stock of ADIA MED, INC. v. Tydus Richards, Case No. 2026CA002155 (the “Action”). The Action is a declaratory-judgment proceeding seeking to quiet title in 29,059,792 shares of the Company’s non-preferred common stock (the “Subject Shares”). The Complaint alleges that the Subject Shares represent 30.78% of the Company’s issued and outstanding shares. The caption names Tydus Richards as the defendant. The Complaint alleges, among other things, that in January 2024 a change of control of the Company occurred when all Special 2022 Series A Preferred stock, carrying 60% of the voting rights, was acquired by Legends Investment Properties, LLC, a Florida limited liability company; that, in connection with that acquisition, the Company determined there was no basis in its records, and no record at its transfer agent of original issuance, supporting the Claimants’ positions as reflected on the shareholder list; that the Claimants’ asserted interests rest solely on the stock transfer ledger; and that, upon information and belief, the Claimants never paid for the Subject Shares and the Subject Shares were not validly issued. The Complaint seeks a judgment declaring that title to the improperly issued Subject Shares is quieted in the Company, and an order restraining each Claimant from instituting an action against the Company for recovery of the Subject Shares or any part of them, together with such other relief as the court deems just and proper. The Company is the plaintiff in the Action. No responsive pleading has been filed, and no hearing has been set, as of the date of this report. The Company intends to pursue the Action. The outcome is uncertain. The Claimants may appear, contest jurisdiction or venue, assert that the Subject Shares were validly issued or transferred, or bring related claims. An adverse result would leave the Subject Shares outstanding in the names of the Claimants. A judgment quieting title in the Company would, if entered and given effect by the transfer agent, reduce the number of shares of common stock deemed issued and outstanding by up to 29,059,792 shares. The Company has not cancelled the Subject Shares, and it will not treat the Subject Shares as retired unless and until a court of competent jurisdiction so orders and the transfer agent records the cancellation. The Company cannot predict the timing or outcome of the Action, or the amount of legal expense it will incur.

 

 

 

 

 32 

 

 

NOTE 16 – SUBSEQUENT EVENTS

 

Management has evaluated subsequent events through the date these condensed consolidated financial statements were available to be issued. Based on our evaluation, the following material events have occurred that require further disclosure:

 

·On October 9, 2026, The Company fully repaid and discharged its unsecured revolving line of credit facility originally entered into on June 30, 2024, between Larry Powalisz, Chief Executive Officer of the Company, as lender (the “Lender”), and the Company (and its relevant subsidiaries, as applicable), as borrower. The Facility had been increased over time to a commitment of $1,000,000 by the Lender, to best accommodate the growth needs of the Company, and bore interest at 6% per annum calculated daily.
   
·On October 13, 2026, the Company entered into a Membership Interest Purchase Agreement (the “Agreement”) with Larry A. Powalisz, the Company’s Chief Executive Officer (the “Buyer”), Adia Labs LLC, a Florida limited liability company (the “LLC”), Live Oak Health LLC d/b/a QCM Biologics (“Live Oak”), and the Company’s independent directors Monica Sher, M.D. and Richard Edwards, D.O. Pursuant to the Agreement, the Company sold seven (7) units of membership interest (the “Purchased Units”) in the LLC to the Buyer for an aggregate purchase price of Three Hundred Fifty Thousand and 00/100 Dollars ($350,000.00) paid entirely in cash. The Purchased Units constitute a seven percent (7%) membership interest in the LLC [assuming one hundred (100) issued units and no other units issued or transferred at closing] and carry seven percent (7%) of the total voting power of the LLC. Economic ownership follows the Units. The Agreement requires that the Company’s operating agreement be amended at closing to reflect the Purchased Units and the voting power. The Agreement includes covenants regarding the use of proceeds from the Purchase Price. These proceeds may be used for Company or Seller corporate purposes only as jointly approved in writing by both Independent Directors, Monica Sher, M.D., and Richard Edwards, D.O. Larry A. Powalisz shall have no unilateral authority to approve, direct, or make any decision concerning the use of the Purchase Price. The Buyer is a related party of the Company, being its Chief Executive Officer. The Independent Directors have acknowledged the Agreement in their capacity as independent directors of the Company. 

 

 

 

 

 

 

 33 

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion and analysis of the financial condition and results of operations of Adia Nutrition, Inc.. and its consolidated subsidiaries (collectively, the “Company”) should be read in conjunction with our condensed consolidated financial statements and the accompanying notes thereto included elsewhere in this Quarterly Report on Form 10-Q. References in this Management’s Discussion and Analysis of Financial Condition and Results of Operations to “us,” “we,” “our,” and similar terms refer to the Company. This Quarterly Report on Form 10-Q includes forward-looking statements, as that term is defined in the federal securities laws, based upon current expectations that involve risks and uncertainties, such as plans, objectives, expectations and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors. Words such as “anticipate,” “estimate,” “plan,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions are used to identify forward-looking statements.

 

We caution you that these statements are not guarantees of future performance or events and are subject to a number of uncertainties, risks and other influences, many of which are beyond our control, which may influence the accuracy of the statements and the projections upon which the statements are based. Reference is made to the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2026.

 

Results of Operations

 

For the nine months ended September 30, 2026 and 2025

 

Revenue

 

For the nine months ended September 30, 2026 and 2025, the Company revenues of $1,019,245 and $521,958, respectively. Revenue was generated from the following sources:

   For the nine months ended   For the nine months ended 
   September 30, 2026   September 30, 2025 
Sales of supplements  $–    0.0%   $3,393    0.7% 
Medical procedures   576,770    56.6%    198,600    38.0% 
Sales of biologics   433,260    42.5%    313,010    60.0% 
Services   –    –    2,267    0.4% 
Shipping and delivery   9,215    0.9%    4,688    0.9% 
Total Revenue  $1,019,245    100.0%   $521,958    100.0% 

 

 

 

 34 

 

 

Gross Profit

 

For the nine months ended September 30, 2026 and 2025, cost of revenue was $544,907 and $278,497, respectively. Cost of revenue was as a result of the following:

 

   For the nine months ended   For the nine months ended 
   September 30, 2026   September 30, 2025 
Cost of supplements  $–    0.0%   $1,057    0.4% 
Cost for administration of medical procedures   160,674    29.5%    93,315    33.5% 
Cost of biologics   384,233    70.5%    184,125    66.1% 
Total Cost of Revenue  $544,907    100.0%   $278,497    100.0% 

 

As a result, our gross profit for the nine months ended September 30, 2026 and 2025, was $474,338 and $243,461, respectively.

 

Operating Expenses

 

For the nine months ended September 30, 2026 and 2025, we incurred total operating expenses of $710,379 and $391,390. The following is a tabular breakdown of our operating expenses for the nine months ended September 30, 2026 and 2025:

         
  

For the nine months ended

September 30,

 
   2026   2025 
Operating Expenses          
General and administrative  $90,187   $129,119 
Advertising and promotion   75,843    54,979 
Clinical trial fees   16,275    – 
Corporate filing fees   17,299    – 
Equipment leases   21,338    20,088 
Legal and professional fees   236,323    104,976 
Public relations   7,320    – 
Repairs and maintenance   2,638    – 
Rent   52,749    48,242 
Research and development   4,375    30,808 
Salaries and wages   177,263    – 
Utilities   4,428    – 
Depreciation and amortization   4,341    3,178 
Total Operating Expenses  $710,379   $391,390 

 

 

 

 35 

 

 

Other Income (Expenses)

 

For the nine months ended September 30, 2026 and 2025, we had other income of $875 and $250, respectively. For the nine months ended September 30, 2026 and 2025, we had other expenses of $36,756 and $22,160, respectively. For the nine months ended September 30, 2026, other income was comprised of interest income on a loan we extended to a start-up facility. For the nine months ended September 30, 2026 and 2025, other expenses were comprised of interest expenses on our line of credit facility with a related party.

 

For the three months ended September 30, 2026 and 2025

 

Revenue

 

For the three months ended September 30, 2026 and 2025, the Company revenues of $454,385 and $332,048, respectively. Revenue was generated from the following sources:

 

   For the three months ended   For the three months ended 
   September 30, 2026   September 30, 2025 
Sales of supplements  $–    0.0%   $1,238    0.4% 
Medical procedures   238,900    52.6%    101,900    30.7% 
Sales of biologics   211,735    46.6%    225,510    67.9% 
Services   –    –    –    – 
Shipping and delivery   3,750    .8%    3,400    1.0% 
Total Revenue  $454,385    100.0%   $332,048    100.0% 

 

Gross Profit

 

For the three months ended September 30, 2026 and 2025, cost of revenue was $233,404 and $128,563, respectively. Cost of revenue was as a result of the following:

 

   For the three months ended   For the three months ended 
   September 30, 2026   September 30, 2025 
Cost of supplements  $–    0.0%   $395    0.3% 
Cost for administration of medical procedures   7,124    3.1%    22,528    17.5% 
Cost of biologics   226,280    96.9%    105,640    82.2% 
Total Cost of Revenue  $233,404    100.0%   $128,563    100.0% 

 

As a result, our gross profit for the three months ended September 30, 2026 and 2025, was $220,981 and $203,485, respectively.

 

 

 

 36 

 

 

Operating Expenses

 

For the three months ended September 30, 2026 and 2025, we incurred total operating expenses of $260,131 and $124,285. The following is a tabular breakdown of our operating expenses for the nine months ended September 30, 2026 and 2025: 

         
  

For the three months ended

September 30,

 
   2026   2025 
Operating Expenses          
General and administrative  $33,234   $56,707 
Advertising and promotion   16,400    23,794 
Clinical trial fees   4,250    – 
Corporate filing fees   5,571    – 
Equipment leases   7,946    8,928 
Legal and professional fees   75,592    11,162 
Public relations   2,400    – 
Repairs and maintenance   476    – 
Rent   16,818    16,240 
Research and development   4,375    6,192 
Salaries and wages   89,532    – 
Utilities   1,890    – 
Depreciation and amortization   1,647    1,262 
Total Operating Expenses  $260,131   $124,285 

 

Other Income (Expenses)

 

For the three months ended September 30, 2026 and 2025, we had other income of $125 and $250, respectively. For three months ended September 30, 2026 and 2025, we had other expenses of $13,990 and $9,074, respectively. For the three months ended September 30, 2026, other income was comprised of interest income on a loan we extended to a start-up facility. For the nine months ended September 30, 2026 and 2025, other expenses were comprised of interest expenses on our line of credit facility with a related party.

 

Liquidity and Capital Resources

 

For the nine months ended September 30, 2026, we had a net loss of $271,922. For the nine months ended September 30, 2026, we had non cash charges of $4,341 in depreciation, $42,215 in amortization of operating lease right-of-use asset, and $17,747 in the amortization of finance lease right-of-use asset. For the nine months ended September 30, 2026, we had an increase in accounts receivable of $20,500, an increase in inventory of $323,475, an decrease in pre-paid expenses of $5,197, a increase in undeposited funds of $4,900, a decrease in receivable on sale of inventory asset of $376, an increase in accounts payable of $190,412, an increase in accrued interest on our line of credit of $36,757, an increase in deferred revenue of $126,300, and a decrease in operating lease liabilities of $42,201. As a result, we had net cash used in operating activities of $239,653 for the nine months ended September 30, 2026.

 

 

 

 37 

 

 

For the nine month ended September 30, 2025, we had a net loss of $169,839. For the nine months ended September 30, 2025, we had non cash charges of $3,178 in depreciation and amortization, $39,075 in amortization of operating lease right-of-use asset, and $12,683 in the amortization of finance lease right-of-use asset. For the nine months ended September 30, 2025, we had an increase in accounts receivable of $105,721, a decrease in inventory of $99,168, a decrease in pre-paid expenses of $25,667, a decrease in accounts payable of $2,504, an increase in accrued interest on our line of credit of $22,159, and a decrease in operating lease liabilities of $32,540. As a result, we had net cash used in operating activities of $108,521 for the nine months ended September 30, 2025.

 

Investing Activities

 

For the nine months ended September 30, 2026, we purchased additional equipment in the amount of $15,436, and provided additional funds to clinics in the amount of $5,300. As a result, we had net cash used in investing activities of $20,736.

 

For the nine months ended September 30, 2025, purchase additional furniture and equipment in the amount of $13,199, provided funds to start-up clinic operations in the amount of $25,000, and we disposed of the Biolete trademarks totaling $5,611. As a result, we had net cash used in investing activities of $32,588.

 

Financing Activities

 

For the nine months ended September 30, 2026, we made payments on our finance lease obligation of $16,497, and we drew down on our line of credit facility for an additional $335,312, and we had proceeds from the sale of a membership interest in our Adia Labs subsidiary of $1,000,000 (the total of the investment was $1,500,000 of which $500,000 is logged as a note receivable). As a result, we had net cash provided by financing activities of $1,318,815.

 

For the nine months ended September 30, 2025, we made payments on our finance lease obligation of $12,683, had proceeds from the sale of our common stock of $70,000, and we drew down on our line of credit facility for an additional $231,471. As a result, we had net cash provided by financing activities of $288,788.

 

Plan of Operation

 

Over the next twelve months, we expect to incur costs and expenses related to:

 

  · maintaining our corporate existence, such as annual fees due to the State of Nevada and any other state in which we conduct business;
  · filing periodic reports under the Exchange Act, including filing, accounting and legal fees;
  · operating our business in a proper and ethical manner.

 

We expect to incur costs associated with filing reports under the Exchange Act over the next twelve months of approximately $100,000. Costs associated with operating our business based upon current operating expenses are projected to be in the range of $450,000 to $750,000. We anticipate our cost of revenue to be approximately 35% to 45% of revenue. Based upon our performance during 2025 and 2024, and the current year to date, we anticipate that our expenses should be able to be satisfied by our profitability, although this can not be assured. If we are unable to cover our expenses with our gross profit, we may be required to obtain capital from third parties.

 

 

 

 38 

 

 

Going Concern

 

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company generated revenues of $1,019,245 for the nine months ended September 30, 2026, with an associated net loss of $271,922, and at September 30, 2026, the Company has an accumulated deficit of $16,245,404 and working capital of $128,369. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time. The Company’s continuation as a going concern for one year after the audit report is dependent upon, among other things, its ability to generate greater revenues and its ability to obtain capital from third parties. No assurance can be given that the Company will be successful in these efforts.

 

Management anticipates continued growth in revenue and plans to utilize the funding resources it has available (i.e., its line of credit facility) as well as the continued identification of adequate sources of funding to provide bridge capital, financing of receivables, and operating capital for continued growth.

 

The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

Off-balance Sheet Arrangements

 

As of September 30, 2026, we did not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

Critical Accounting Policies

 

Basis of Presentation

 

The Company’s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Management further acknowledges that it is solely responsible for adopting sound accounting practices, establishing and maintaining a system of internal accounting control and preventing and detecting fraud. The Company's system of internal accounting control is designed to assure, among other items, that (1) recorded transactions are valid; (2) valid transactions are recorded; and (3) transactions are recorded in the proper period in a timely manner to produce consolidated financial statements which present fairly the financial condition, results of operations and cash flows of the Company for the respective periods being presented.

 

 

 

 39 

 

 

Use of Estimates

 

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Revision of Previously Issued Financials

 

In connection with the preparation of the Company’s financial statements for the three and nine months ended September 30, 2026, management identified an immaterial error in the previously issued financial statements for the three and six months ending June 30, 2026.

 

Management evaluated the error under SAB Topic 1.M (SAB 99) and SAB Topic 1.N (SAB 108) and concluded that the error was not material to the previously issued financial statements. Accordingly, the Company has revised the financial statements for the three and six months ended June 30, 2026, presented herein to correct the error.

 

The Company identified an immaterial error in the financial statements related to the allocation of deferred revenue to incurred revenue related to IRB studies (rolled up in “medical procedures” revenues). Initially, the Company amortized the incurred revenue over the portion of the IRB study related to the “treatment phase” of the patients. However, considering that the Company continued to incur costs associated with an option for the study participants to continue their treatment over a “crossover period” post conclusion of the treatment phase, the Company found it more accurate to recognize and amortize the revenue of the IRB study over the period to include both the treatment phase and the optional crossover period.

 

Going forward, the same methodology will be applied to future IRB studies. The error was previously evaluated and determined not to be material to the Company’s financial statements.

 

After giving effect to this correction during the three and six month ended June 30, 2026, there are no impacts to retained earnings nor shareholder’s equity (deficit) as relates to the three and nine months ended September 30, 2026, as the initial IRB that cause this amortization of revenue to come to our attention concluded prior to the end of September 30, 2026.

 

Therefore, the only impact is to revenue and the net income for the three and six months ended June 30, 2026. The only permanent impact to retained earnings at June 30, 2026, thereby impacting stockholders’ equity (deficit) as of June 30, 2026. In addition, the Company carried an additional $96,800 in deferred revenue on its balance sheet at June 30, 2026, to offset the aforementioned adjustments effectively.

 

 

 

 40 

 

 

ADIA MED, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

 

  

For the Three Months Ended

June 30, 2026

(as reported)

   Topside Adjustment  

For the Three Months Ended

June 30, 2026

(revised)

 
Revenue               
Sales of supplements  $–   $–   $– 
Medical procedures   329,820    (96,800)   233,020 
Sales of biologics   151,750    –    151,750 
Services   –    –    – 
Shipping and delivery   3,815    –    3,815 
Total Revenue   485,385    (96,800)   388,585 
                
Cost of Revenue               
Supplements   –    –    – 
Procedures   82,588    –    82,588 
Biologics   120,217    –    120,217 
Total Cost of Revenue   202,805    –    202,805 
                
Gross Profit   282,580    (96,800)   185,780 
                
Operating Expenses               
General and administrative   23,175    –    23,175 
Advertising and promotion   22,436    –    22,436 
Clinical trial fees   7,175    –    7,175 
Corporate filing fees   7,723    –    7,723 
Equipment leases   6,696    –    6,696 
Legal and professional fees   81,922    –    81,922 
Public relations   2,480    –    2,480 
Repairs and maintenance   1,152    –    1,152 
Rent   19,748    –    19,748 
Research and development   –    –    – 
Salaries and wages   55,129    –    55,129 
Utilities   1,672    –    1,672 
Depreciation and amortization   1,443    –    1,443 
Total Operating Expenses   230,751    –    230,751 
                
Income (Loss) from Operations   51,829    (96,800)   (44,971)
                
Other Income (Expense)               
Interest income   375    –    375 
Interest expense – related party   (11,786)   –    (11,786)
Total Other Income (Expense)   (11,411)   –    (11,411)
                
Net Income (Loss) Before provision for Income Taxes   40,418    (96,800)   (56,382)
                
Provision for Income Taxes   –    –    – 
                
NET INCOME (LOSS)  $40,418   $(96,800)  $(56,382)

 

 

 

 41 

 

 

  

For the Six Months Ended

June 30, 2026

(as reported)

   Topside Adjustment  

For the Six Months Ended

June 30, 2026

(revised)

 
Revenue               
Sales of supplements  $–   $–   $– 
Medical procedures   434,670    (96,800)   337,870 
Sales of biologics   221,525    –    221,525 
Services   –    –    – 
Shipping and delivery   5,465    –    5,465 
Total Revenue   661,660    (96,800)   564,860 
                
Cost of Revenue               
Supplements   –    –    – 
Procedures   153,550    –    153,550 
Biologics   157,953    –    157,953 
Total Cost of Revenue   311,503    –    311,503 
                
Gross Profit   350,157    (96,800)   253,357 
                
Operating Expenses               
General and administrative   56,952    –    56,952 
Advertising and promotion   59,443    –    59,443 
Clinical trial fees   12,025    –    12,025 
Corporate filing fees   11,728    –    11,728 
Equipment leases   13,392    –    13,392 
Legal and professional fees   160,731    –    160,731 
Public relations   4,920    –    4,920 
Repairs and maintenance   2,162    –    2,162 
Rent   35,931    –    35,931 
Research and development   –    –    – 
Salaries and wages   87,731    –    87,731 
Utilities   2,538    –    2,538 
Depreciation and amortization   2,695    –    2,695 
Total Operating Expenses   450,248    –    450,248 
                
Income (Loss) from Operations   (100,091)   (96,800)   (196,891)
                
Other Income (Expense)               
Interest income   750    –    750 
Interest expense – related party   (22,766)   –    (22,766)
Total Other Income (Expense)   (22,016)   –    (22,016)
                
Net Income (Loss) Before provision for Income Taxes   (122,107)   (96,800)   (218,907)
                
Provision for Income Taxes   –    –    – 
                
NET INCOME (LOSS)  $(122,107)  $(96,800)  $(218,907)

 

 

 

 42 

 

 

ADIA MED, INC.

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY (DEFICIT) (UNAUDIITED)

                                 
   Special 2022 Series A Preferred   Series A Preferred   Series C Preferred   Shares to be issued 
   Shares   Amount ($)   Shares   Amount ($)   Shares   Amount ($)   Shares   Amount ($) 
Balance December 31, 2025   1    1    –    –    1,750,000    1,750    2,875,000    152,607 
                                         
Net loss   –    –    –    –    –    –    –    – 
Balance March 31, 2026   1    1    –    –    1,750,000    1,750    2,875,000    152,607 
                                         
Net loss   –    –    –    –    –    –    –    – 
Balance June 30, 2026   1    1    –    –    1,750,000    1,750    2,875,000    152,607 

(continued)

                             
   Class A Common Stock   Class B Common Stock   Additional Paid-In   Accumulated  

Total

Stockholders’

Equity

 
   Shares   Amount ($)   Shares   Amount ($)   Capital ($)   Deficit ($)   (Deficit) ($) 
Balance December 31, 2025   94,404,696    94,405    –    –    15,467,045    (15,973,482)   (257,674)
                                    
Net loss   –    –    –    –    –    (162,525)   (162,525)
Balance March 31, 2026   94,404,696    94,405    –    –    15,467,045    (16,136,007)   (420,199)
                                    
Net loss   –    –    –    –    –    (56,382)   (56,382)
Balance June 30, 2026   94,404,696    94,405    –    –    15,467,045    (16,192,389)   (476,581)

 

Principles of Consolidation

 

The condensed consolidated financial statements have been prepared in accordance with GAAP. The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries (Biolete, LLC, Adia Med of Winter Park, LLC and Adia Labs, LLC). All intercompany balances and transactions have been eliminated.

 

Cash and Cash Equivalents

 

The Company accounts for cash and cash equivalents under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 305, “Cash and Cash Equivalents,” and considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.

 

 

 

 43 

 

 

Revenue Recognition

 

The Company records transactions in accordance with ASU 2014-09, “Revenue from Contracts with Customers” and all subsequent amendments to the ASU (collectively, “ASC 606”). In accordance with ASC 606, revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services.

 

Our operations currently generate revenues from the sale of our biologic products, the performance of medical procedures, sales of ancillary products, shipping and delivery, and other services. During the nine months ended September 30, 2026 and 2025, the Company had revenues of $1,019,245 and $521,958, respectively. Revenue was generated from the following sources:

                 
   September 30, 2026   September 30, 2025 
Sales of supplements  $–    0.0%   $3,393    0.7% 
Medical procedures   576,770    56.6%    198,600    38.0% 
Sales of biologics   433,260    42.5%    313,010    60.0% 
Services   –    –    2,267    0.4% 
Shipping and delivery   9,215    0.9%    4,688    0.9% 
Total Revenue  $1,019,245    100.0%   $521,958    100.0% 

 

Income Taxes and Valuation Allowance

 

The Company accounts for income taxes under ASC 740, “Income Taxes”. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. All of the Company’s deferred tax assets were offset by a full valuation allowance for September 30, 2026 and December 31, 2025.

 

Financial Instruments

 

ASC 820, “Fair Value Measurements and Disclosures,” defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

 

 

 

 44 

 

 

  Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
     
  Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
     
  Level 3 - Inputs that are both significant to the fair value measurement and unobservable.

 

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2026. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.

 

The Company does not have any assets or liabilities measured at fair value on a recurring basis.

 

Related Parties

 

The Company follows ASC 850-10, “Related Party Disclosures,” for the identification of related parties and disclosure of related party transactions. The EO and Director of the Company has provided working capital to the Company on the line of credit facility he has extended to the Company.

 

Pursuant to ASC 850-10-20, related parties include: a) affiliates of the Company; b) principal owners of the Company; c) management of the Company; d) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and e) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

 

Material related party transactions are required to be disclosed in the consolidated financial statements, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: a) the nature of the relationship(s) involved; b) a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which statements of operation are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c) the dollar amounts of transactions for each of the periods for which statements of operations are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d) amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.

 

 

 

 45 

 

 

Loss Contingencies

 

From time to time the Company may be subject to various legal proceedings and claims that arise in the ordinary course of business. On at least a quarterly basis, consistent with ASC 450-20-50-1C, if the Company determines that there is a reasonable possibility that a material loss may have been incurred, or is reasonably estimable, regardless of whether the Company accrued for such a loss (or any portion of that loss), the Company will confer with its legal counsel, consistent with ASC 450. If the material loss is determinable or reasonably estimable, the Company will record it in its accounts and as a liability on the condensed consolidated balance sheet.

 

Long-lived Assets

 

Long-lived assets such as fixed assets and identifiable intangibles are reviewed for impairment whenever facts and circumstances indicate that the carrying value may not be recoverable. When required impairment losses on assets to be held and used are recognized based on the fair value of the asset. The fair value is determined based on estimates of future cash flows, market value of similar assets, if available, or independent appraisals, if required. If the carrying amount of the long-lived asset is not recoverable from its undiscounted cash flows, an impairment loss is recognized for the difference between the carrying amount and fair value of the asset. When fair values are not available, the Company estimates fair value using the expected future cash flows discounted at a rate commensurate with the risk associated with the recovery of the assets. We did not recognize any impairment losses for any periods presented.

 

Segment Reporting

 

During the year ended December 31, 2025, the Company had three operating segments: (1) Biolete, (2) Adia Med, and (3) Adia Labs. On September 30, 2025, the Company sold its rights to the Biolete trademarks and all associated assets to Cement Factory, and as a result for the nine months ended September 30, 2026, the Company had two operating segments: (1) Adia Med, and (2) Adia Labs.

         
  

September 30,

2026

   December 31,
2025
 
Adia Med assets  $304,751   $261,208 
Adia Labs assets   1,435,348    25,025 
Unallocated corporate assets   712,888    308,593 
Total Assets  $2,452,987   $594,826 

 

The CODM reviews performance based on gross profit (sales less cost of products or services sold), operating profit, and net income (loss). Profitability is important to the Company’s ability to grow and expand operations. The Company does not have any operations or sources of revenue outside of the United States. Corporate overhead is not allocated to each segment unless the cost is specifically incurred to support the single segment. This provides the CODM with segment specific costs and profits.

 

 

 

 46 

 

 

The Company chooses to disclose the following in its segment reporting requirements for the nine months ended September 30, 2026:

                     

For the nine months ended

September 30, 2026

  Unallocated                 
   Corporate       ADIA   ADIA     
   Overhead   Biolete   Med   Labs   Totals 
Segment Revenue                         
Medical procedures  $–   $–   $576,770   $–   $576,770 
Sales of biologics, net of discounts and refunds   –    –    –    433,260    433,260 
Shipping and delivery   –    –    –    9,215    9,215 
Total Segment Revenue   –    –    576,770    442,475    1,019,245 
                          
Cost of Revenue                         
Cost of goods sold   –    –    160,674    384,233    544,907 
                          
Gross Profit   –    –    416,096    58,242    474,338 
                          
Operating Expenses                         
General and administrative   353,287    –    241,517    39,732    634,536 
Advertising and promotion   1,126    –    74,717    –    75,843 
Segment Operating Expenses   354,413    –    316,234    39,732    710,379 
                          
Segment Profit (Loss)  $(354,413)  $–   $99,862   $18,510   $(236,041)

 

 

 

 47 

 

 

The Company chooses to disclose the following in its segment reporting requirements for the nine months ended September 30, 2025:

                     

For the nine months ended

September 30, 2025

  Unallocated                 
   Corporate       ADIA   ADIA     
   Overhead   Biolete   Med   Labs   Totals 
Segment Revenue                         
Medical procedures  $–   $–   $198,600   $–   $198,600 
Sales of biologics, net of discounts and refunds   –    –    –    313,010    313,010 
Sales of supplements   –    3,393    –    –    3,393 
Services   2,267    –    –         2,267 
Shipping and delivery   –    –    –    4,688    4,688 
Total Segment Revenue   2,267    3,393    198,600    317,698    521,958 
                          
Cost of Revenue                         
Cost of goods sold   –    1,057    93,315    184,125    278,497 
                          
Gross Profit   2,267    2,336    105,285    133,573    243,461 
                          
Operating Expenses                         
General and administrative   182,085    2,226    147,902    4,198    336,411 
Advertising and promotion   25,349    67    24,497    5,066    54,979 
Segment Operating Expenses   207,434    2,293    172,399    9,264    391,390 
                          
Segment Profit (Loss)  $(205,167)  $42   $(67,114)  $124,309   $(147,929)

 

 

 

 48 

 

 

Stock-Based Compensation

 

FASB ASC 718 “Compensation – Stock Compensation,” prescribes accounting and reporting standards for all stock-based payments award to employees, including employee stock options, restricted stock, employee stock purchase plans and stock appreciation rights, may be classified as either equity or liabilities. The Company determines if a present obligation to settle the share-based payment transaction in cash or other assets exists. A present obligation to settle in cash or other assets exists if: (a) the option to settle by issuing equity instruments lacks commercial substance or (b) the present obligation is implied because of an entity’s past practices or stated policies. If a present obligation exists, the transaction should be recognized as a liability; otherwise, the transaction should be recognized as equity.

 

The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of FASB ASC 505-50 “Equity – Based Payments to Non-Employees.” Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date. For the three and nine months ended September 30, 2026 and 2025, the Company had no share-based compensation.

 

Recently Issued Accounting Pronouncements

 

We have reviewed the FASB issued ASU accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted accounting principles and does not believe that any new or modified principles will have a material impact on the corporation’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration. For the year ended December 31, 2025, we adopted the ASU 2023-09, “Income Taxes (Topic 740) Improvement to Income Tax Disclosure”, to appropriately reconcile to specific tax rate provisions.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

As a smaller reporting company, the Company is not required to provide the information required by this Item.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in company reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure.

 

 

 

 49 

 

 

As required by Rules 13a-15 and 15d-15 under the Exchange Act, our principal executive officer and principal financial officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures concluded as of September 30, 2026. Based upon this evaluation, our principal executive officer and principal financial officer concluded as of September 30, 2026, our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were not effective.

 

We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we have detected all our control deficiencies and instances of fraud, if any. The design of disclosure controls and procedures also is based partly on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

 

Changes in Internal Controls over Financial Reporting

 

During the nine months ended September 30, 2026, there has been no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 

 

 

 

 

 

 

 

 50 

 

 

PART II – OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

From time to time, we may be involved in various claims and legal actions arising in the ordinary course of business. To the knowledge of our management, there are no legal proceedings currently pending against us which we believe would have a material effect on our business, financial position or results of operations and, to the best of our knowledge, there are no such legal proceedings contemplated or threatened.

 

On May 5, 2025, the Company retired 15,495,165 shares of its Common Stock and declared void 10,000,000 shares of the Company Series A Preferred Shares. Initially, on May 31, 2024, the Company filed a complaint for declaratory relief, seeking an order declaring as void a total of 15,495,165 shares of the Company’s issued and outstanding shares of Common Stock, held by Lotus Fund (“Lotus”) (10,495,165 shares), and Jason S. Coombs (“Coombs”) (5,000,000 shares). In addition, the lawsuit seeks an order declaring as void a total of 10,000,000 shares of the Company’s issued and outstanding shares of Series A Preferred Shares, held by Shelly Singhal (“Singhal”). Lotus, Coombs and Singhal (collectively the “Claimants”) were issued these shares but the Company deems that they were not properly acquired through any consideration. The lawsuit (Case Number: 2024CA001088, Case Style: ADIA NUTRITION INC -VS- ADIA NUTRITION INC) was filed pursuant to the laws of the State of Florida, and the venue lies in Seminole County. This matter was settled in favor of the Company on May 5, 2025.

 

On September 16, 2026, the Company filed a Verified Complaint for Declaratory Judgement (the “Complaint”) in the Circuit Court of the Eighteenth Judicial Circuit in and for Seminole County, Florida, styled In Re Stock of ADIA MED, INC. v. Tydus Richards, Case No. 2026CA002155 (the “Action”). The Action is a declaratory-judgment proceeding seeking to quiet title in 29,059,792 shares of the Company’s non-preferred common stock (the “Subject Shares”). The Complaint alleges that the Subject Shares represent 30.78% of the Company’s issued and outstanding shares. The caption names Tydus Richards as the defendant. The Complaint alleges, among other things, that in January 2024 a change of control of the Company occurred when all Special 2022 Series A Preferred stock, carrying 60% of the voting rights, was acquired by Legends Investment Properties, LLC, a Florida limited liability company; that, in connection with that acquisition, the Company determined there was no basis in its records, and no record at its transfer agent of original issuance, supporting the Claimants’ positions as reflected on the shareholder list; that the Claimants’ asserted interests rest solely on the stock transfer ledger; and that, upon information and belief, the Claimants never paid for the Subject Shares and the Subject Shares were not validly issued. The Complaint seeks a judgment declaring that title to the improperly issued Subject Shares is quieted in the Company, and an order restraining each Claimant from instituting an action against the Company for recovery of the Subject Shares or any part of them, together with such other relief as the court deems just and proper. The Company is the plaintiff in the Action. No responsive pleading has been filed, and no hearing has been set, as of the date of this report. The Company intends to pursue the Action. The outcome is uncertain. The Claimants may appear, contest jurisdiction or venue, assert that the Subject Shares were validly issued or transferred, or bring related claims. An adverse result would leave the Subject Shares outstanding in the names of the Claimants. A judgment quieting title in the Company would, if entered and given effect by the transfer agent, reduce the number of shares of common stock deemed issued and outstanding by up to 29,059,792 shares. The Company has not cancelled the Subject Shares, and it will not treat the Subject Shares as retired unless and until a court of competent jurisdiction so orders and the transfer agent records the cancellation. The Company cannot predict the timing or outcome of the Action, or the amount of legal expense it will incur.

 

 

 

 

 51 

 

 

ITEM 1A. RISK FACTORS

 

As a smaller reporting company, the Company is not required to provide the information required by this Item.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

During the three and nine months ended September 30, 2026, the Company did not issue any unregistered equity securities.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

None.

 

There have been no material changes to the procedures by which security holders may recommend nominees to our Board of Directors since we last provided disclosure in response to the requirements of Item 407(c)(3) of Regulation S-K promulgated under the Exchange Act.

 

During the quarter ended September 30, 2026, no director or officer of the Company adopted or terminated a contract, instruction or written plan for the purchase or sale of securities of the Company intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) and/or a non-Rule 10b5-1 trading arrangement.

 

 

 

 

 

 52 

 

 

ITEM 6. EXHIBITS

 

Exhibit No.   Exhibit Description
3.1   Amended and Restated Articles of Incorporation Adia Nutrition 1-22-2024
3.1.1   Bylaws of Adia Nutrition
4.2.1   ADIA - Biolete – Membership Interest Purchase Agreement 7-11-2024
4.2.2   ADIA – Cement Factory Signed Membership Interest Agreement 9-24-2024
4.2.3   ADIA - Biolete – Sale of Assets to Cement Factory 9-22-2025
5.1.1   Sher – Independent Director Agreement 8-19-2024
5.1.2   Edwards – Independent Director Agreement 9-10-2024
5.1.3   Barot – Independent Director Agreement 9-23-2024
5.1.4   Thomas – Independent Director Agreement 10-13-2025
31.1*   Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act
31.2*   Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act
32.1*   Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act
32.2*   Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act
101.INS*   Inline XBRL Instance Document
101.SCH*   Inline XBRL Schema Document
101.CAL*   Inline XBRL Calculation Linkbase Document
101DEF*   Inline XBRL Definition Linkbase Document
101.LAB*   Inline XBRL Label Linkbase Document
101.PRE *   Inline XBRL Presentation Linkbase Document
104*   Cover Page Interactive Data File (formatted in inline XBRL, and included in exhibit 101).

 

* Filed or furnished herewith.

 

 

 

 

 

 53 

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  ADIA Nutrition, Inc.
     
     
Date: November 16, 2026 By:

/s/ Larry Powalisz

    Name: Larry Powalisz
    Title: Chief Executive Officer
     
     
  ADIA Nutrition, Inc.
     
     
Date: November 16, 2026 By:

/s/ Rebecca Miller

    Name: Rebecca Miller
    Title: Chief Financial Officer

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Name

 

Position

 

Date

         

/s/ Larry Powalisz

  Chief Executive Officer and Director   November 16, 2026
Larry Powlalisz        
         

/s/ Rebecca Miller

  Chief Financial Officer   November 16, 2026
Rebecca Miller        
         
/s/ Evan Thomas   Director   November 16, 2026
Evan Thomas        
         
/s/ Kalpesh Barot   Director   November 16, 2026
Kalpesh Barot        
         
/s/ Monica Sher   Director   November 16, 2026
Monica Sher        
         
/s/ Richard Edwards   Director   November 16, 2026
Richard Edwards        

 

 

 

 54 

Keep reading